WO2023104062A1 - B7h6抗体及其应用 - Google Patents

B7h6抗体及其应用 Download PDF

Info

Publication number
WO2023104062A1
WO2023104062A1 PCT/CN2022/137095 CN2022137095W WO2023104062A1 WO 2023104062 A1 WO2023104062 A1 WO 2023104062A1 CN 2022137095 W CN2022137095 W CN 2022137095W WO 2023104062 A1 WO2023104062 A1 WO 2023104062A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
antibody
seq
amino acid
acid sequence
Prior art date
Application number
PCT/CN2022/137095
Other languages
English (en)
French (fr)
Inventor
田志刚
曹国帅
肖卫华
孙汭
孙昊昱
Original Assignee
合肥天港免疫药物有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 合肥天港免疫药物有限公司 filed Critical 合肥天港免疫药物有限公司
Priority to AU2022404479A priority Critical patent/AU2022404479A1/en
Priority to IL310514A priority patent/IL310514A/en
Priority to EP22903484.8A priority patent/EP4378956A1/en
Priority to MX2024003129A priority patent/MX2024003129A/es
Priority to CA3227094A priority patent/CA3227094A1/en
Priority to KR1020247004588A priority patent/KR20240032996A/ko
Priority to JP2024506277A priority patent/JP2024529526A/ja
Publication of WO2023104062A1 publication Critical patent/WO2023104062A1/zh
Priority to ZA2024/00968A priority patent/ZA202400968B/en
Priority to US18/584,875 priority patent/US20240190968A1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Definitions

  • the present invention relates to the field of antibodies, in particular to an antibody capable of binding to B7H6 or an antigen-binding fragment thereof and use thereof.
  • NK cells are very important innate-like lymphocytes in the body and play an important role in anti-virus and anti-tumor.
  • NK cells express a variety of activating receptors on the surface, including NKp30, NKG2D, etc., which recognize and bind to ligands expressed on the surface of tumor cells. These ligands are encoded by their own genes and expressed under conditions such as malignant transformation of cells (tumors) on the cell surface.
  • NKp30 is an important NK cell activating receptor. After binding to its ligand, NKp30 transmits activation signals and promotes NK cells to kill tumors.
  • B7H6 is the only known NKp30 ligand expressed in the form of a membrane protein. B7-H6 is highly expressed in a variety of tumor tissues such as melanoma and liver cancer, but not in normal tissues, and has tumor specificity.
  • Cytokines such as TGF- ⁇ in the tumor microenvironment down-regulate the expression of NKp30 on the surface of NK cells, resulting in the inability of NK cells to accurately recognize and kill tumors through the interaction of NKp30-B7H6, resulting in tumor immune escape. Therefore, it is necessary to provide a therapeutic antibody drug targeting B7H6.
  • the purpose of the present invention is to overcome the deficiencies of the prior art and provide a B7H6 antibody capable of binding to human and monkey B7H6 and promoting the binding of B7H6 to NKp30 and its use.
  • the antibody provided by the invention promotes the anticancer function of NK cells by promoting the combination of B7H6 and NKp30.
  • the present invention provides an antibody or antigen-binding fragment thereof capable of binding to B7H6, wherein the antibody or antigen-binding fragment thereof comprises heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3, and light chain CDR1, light chain chain CDR2 and light chain CDR3, wherein,
  • the heavy chain CDR1 comprises at least one amino acid sequence selected from the amino acid sequences shown in SEQ ID NO:1, SEQ ID NO:7 and conservatively modified forms thereof;
  • the heavy chain CDR2 comprises at least one amino acid sequence selected from the amino acid sequences shown in SEQ ID NO: 2, SEQ ID NO: 8 and conservatively modified forms thereof;
  • the heavy chain CDR3 comprises at least one of the amino acid sequences selected from the amino acid sequences shown in SEQ ID NO:3, SEQ ID NO:9 and conservatively modified forms thereof;
  • the light chain CDR1 comprises at least one amino acid sequence selected from the amino acid sequences shown in SEQ ID NO:4, SEQ ID NO:10 and conservatively modified forms thereof;
  • the light chain CDR2 comprises at least one of amino acid sequences from the amino acid sequences shown in SEQ ID NO:5, SEQ ID NO:11 and conservatively modified forms thereof;
  • the light chain CDR3 contains at least one amino acid sequence selected from the amino acid sequences shown in SEQ ID NO: 6, SEQ ID NO: 12 and conservatively modified forms thereof.
  • the antibody or antigen-binding fragment thereof comprises:
  • heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO:1, heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO:2, and heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO:3,
  • Light chain CDR1 having the amino acid sequence shown in SEQ ID NO:4
  • light chain CDR2 having the amino acid sequence shown in SEQ ID NO:5
  • light chain CDR3 having the amino acid sequence shown in SEQ ID NO:6: or
  • heavy chain CDR1 having the amino acid sequence shown in SEQ ID NO:7
  • heavy chain CDR2 having the amino acid sequence shown in SEQ ID NO:8
  • heavy chain CDR3 having the amino acid sequence shown in SEQ ID NO:9
  • Light chain CDR1 having the amino acid sequence shown in SEQ ID NO:10
  • light chain CDR2 having the amino acid sequence shown in SEQ ID NO:11
  • light chain CDR3 having the amino acid sequence shown in SEQ ID NO:12.
  • the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, (i) the heavy chain variable region comprising SEQ ID NO: 13, SEQ ID NO: 15 , amino acid sequences shown in SEQ ID NO:17, SEQ ID NO:19 and amino acid sequences of at least one of conservatively modified forms thereof, at least 80% homologous amino acid sequences; and/or, (ii) the light chain can be
  • the variable region comprises amino acids with at least 80% homology to at least one of the amino acid sequences shown in SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20 and the amino acid sequences of modified forms thereof sequence.
  • the heavy chain variable region comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% of the heavy chain variable region selected from (i). % or 100% homologous amino acid sequence; said light chain variable region comprises at least 90%, at least 95%, at least 96%, at least 97%, at least 98% of the light chain variable region selected from (ii). %, amino acid sequences of at least 99% or 100% homology.
  • the antibody or antigen-binding fragment thereof comprises:
  • the antibody or antigen-binding fragment thereof comprises:
  • the isolated antibody is IgG1, IgG2 or IgG4.
  • the antibody is a monoclonal antibody, a murine antibody, a chimeric antibody, a humanized antibody, a human engineered antibody, a human antibody, Fv, a single-chain antibody (scFv), Fab, Fab', Fab' -SH or F(ab') 2 .
  • the antibody or antigen-binding fragment thereof is capable of binding the amino acid sequence set forth in SEQ ID NO:21.
  • the present invention provides an immunoconjugate comprising a therapeutic agent and the above-mentioned antibody or antigen-binding fragment thereof conjugated to the therapeutic agent.
  • the present invention provides a composition, wherein the composition contains the above-mentioned antibody or antigen-binding fragment thereof, and/or the above-mentioned immunoconjugate, and a pharmaceutically acceptable carrier.
  • the present invention provides a kit for detecting B7H6 in a sample, the kit comprising the above antibody or an antigen-binding fragment thereof.
  • the present invention provides the use of the above-mentioned antibody or antigen-binding fragment thereof in the preparation of a reagent for detecting B7H6 in a sample.
  • the present invention provides the use of the above-mentioned antibody or antigen-binding fragment thereof in the preparation of a medicament for preventing and/or treating a B7H6-mediated disease, and the B7H6-mediated disease is cancer or an infectious disease ,
  • the cancer is lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, stomach cancer, esophagus cancer, oral squamous cell carcinoma and head and neck cancer at least one of the cancers.
  • the present invention provides a nucleic acid comprising a nucleic acid encoding the above-mentioned antibody or antigen-binding fragment thereof.
  • the present invention provides a recombinant vector or transformant, which contains the above-mentioned nucleic acid.
  • the present invention provides a recombinant cell carrying the aforementioned nucleic acid, expression vector or transformant or expressing the aforementioned antibody or antigen-binding fragment thereof.
  • the present invention provides a drug, including the aforementioned antibody or antigen-binding fragment thereof, immunoconjugate, composition, drug, nucleic acid, recombinant vector or transformant or recombinant cell.
  • the present invention provides the aforementioned antibodies or antigen-binding fragments thereof, immunoconjugates, compositions, drugs, nucleic acids, recombinant vectors or transformants or recombinant cells in the treatment and/or prevention of B7H6-mediated use in disease.
  • the antibody or its antigen-binding fragment can effectively bind to B7H6, thereby promoting the interaction between B7H6 and NKp30, and strengthening the anti-cancer function of NK cells. Therefore, the antibody or its antigen-binding fragment can be used in The substances obtained by expressing the antibody or its antigen-binding fragment under appropriate conditions can effectively prevent and/or treat diseases mediated by B7H6.
  • the present invention provides a method of treating and/or preventing a B7H6-mediated disease.
  • the method includes administering to the subject at least one of the following: 1) the aforementioned antibody or antigen-binding fragment thereof; 2) the aforementioned immunoconjugate; 3) the aforementioned 4) the aforementioned drug; 5) the aforementioned nucleic acid; 6) the aforementioned recombinant vector or transformant; and 7) the aforementioned recombinant cell.
  • the antibody or its antigen-binding fragment can effectively bind to B7H6, thereby promoting the interaction between B7H6 and NKp30, and strengthening the anti-cancer function of NK cells.
  • the antibody or its antigen-binding fragment can be used in The substance obtained by expressing the antibody or its antigen-binding fragment under appropriate conditions, or the substance comprising the antibody or its antigen-binding fragment can effectively prevent and/or treat B7H6-mediated diseases, according to the method of the embodiment of the present invention It can effectively prevent and/or treat diseases mediated by B7H6.
  • the present invention provides a method of diagnosing whether a subject has a B7H6-mediated disease.
  • the method includes using at least one of the following to detect B7H6 in the sample to be tested: 1) the aforementioned antibody or an antigen-binding fragment thereof; 2) the aforementioned nucleic acid; 3) The aforementioned recombinant vector or transformant; and 4) the aforementioned recombinant cell, based on the detection result of B7H6, determine the content of B7H6 in the sample to be tested.
  • the antibodies or antigen-binding fragments of the embodiments of the present invention can effectively bind to B7H6.
  • the antibodies or antigen-binding fragments can be used to detect B7H6, and B7H6 mediates various diseases. Therefore, according to the subject
  • the level of B7H6 contained in the source biological sample can determine whether the subject suffers from a B7H6-mediated disease.
  • the above-mentioned substances can also be used to monitor the content of B7H6 in the subject's test sample, that is, the above-mentioned substances can also be used for disease staging of subjects suffering from B7H6-mediated diseases, and can also be used for B7H6-mediated diseases. prognostic assessment of the disease.
  • the present invention provides the use of at least one of the following in diagnosing whether a subject suffers from a B7H6-mediated disease: 1) the aforementioned antibody or antigen-binding fragment thereof; 2) the aforementioned nucleic acid; 3) the aforementioned recombinant vector or transformant; and 4) the aforementioned recombinant cell.
  • the antibodies or antigen-binding fragments of the embodiments of the present invention can effectively bind to B7H6. Therefore, the antibodies or antigen-binding fragments can be used to detect B7H6, and B7H6 mediates various diseases. Therefore, according to the subject The level of B7H6 contained in the source biological sample can determine whether the subject suffers from a B7H6-mediated disease.
  • the present invention provides an anti-B7H6 antibody or an antigen-binding fragment thereof capable of binding to human and monkey B7H6.
  • the antibody or antigen-binding fragment thereof of the present invention has at least one of the following properties: capable of binding to human and monkey B7H6; capable of promoting the interaction between B7H6 and NKp30; capable of promoting the anticancer function of NK cells.
  • Figure 1 is a graph showing the ELISA results of the binding of murine B7H6 antibody to human B7H6 according to a specific embodiment of the present invention
  • Fig. 2 is a result diagram of the binding of murine B7H6 antibody to HL60-B7H6 cells according to a specific embodiment of the present invention
  • Fig. 3 is a graph showing ELISA results of humanized B7H6 antibody binding to human B7H6 according to a specific embodiment of the present invention
  • Fig. 4 is a graph showing the results of humanized B7H6 antibody binding to HL60-B7H6 cells according to a specific embodiment of the present invention
  • Figure 5 is a result diagram of the binding of humanized B7H6 antibody to CHO-K1-cyno B7H6 cells according to a specific embodiment of the present invention
  • Fig. 6 is a graph showing ELISA results of humanized B7H6 antibody binding to monkey B7H6 according to a specific embodiment of the present invention.
  • Fig. 7 is a result diagram showing that B7H6 antibody promotes the binding of receptor NKp30 according to a specific embodiment of the present invention.
  • Fig. 8 is a graph showing the results of B7H6 antibody-mediated complement-dependent cytotoxic effect according to a specific embodiment of the present invention.
  • Fig. 9 is a graph showing the results of anti-human acute myeloid leukemia U-937 tumors promoted by the B7H6 antibody in nude mice according to a specific embodiment of the present invention.
  • first and second are only used for descriptive purposes, and cannot be understood as indicating or implying relative importance or implicitly indicating the quantity of indicated technical features. Thus, a feature defined as “first” and “second” may explicitly or implicitly include one or more of these features. Further, in the description of the present invention, unless otherwise specified, "plurality" means two or more.
  • antigen-binding fragments generally refer to antigen-binding antibody fragments, which may include a part of a complete antibody, generally an antigen-binding region or variable regions, examples of antibody fragments include Fab, Fab', F(ab')2, Fv or scFv, diabodies, linear antibodies, single chain antibody molecules and the like.
  • CDR complementarity determining region
  • CDR sequence refers to the amino acid sequence in an antibody that is responsible for antigen binding, for example, generally includes: 23-34(L1), 50-56(L2) in the light chain variable region and 89-97(L3), and the amino acid residues near 31-35B(H1), 50-65(H2) and 95-102(H3) in the heavy chain variable region (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD.
  • conservatively modified amino acid sequence refers to amino acid modifications that do not significantly affect or alter the binding properties of antibodies comprising the amino acid sequence, including amino acid substitutions, additions and deletions. Modifications can be introduced into the antibodies of the invention by standard techniques such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • a conservative amino acid substitution is one in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues having similar side chains have been identified in the art. These families include amino acids with basic side chains (such as lysine, arginine, histidine), amino acids with acidic side chains (such as aspartic acid, glutamic acid), and uncharged polar side chains.
  • Chain amino acids such as glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan
  • amino acids with non-polar side chains such as alanine, valine amino acid, leucine, isoleucine, proline, phenylalanine, methionine
  • amino acids with ⁇ -branched side chains such as threonine, valine, isoleucine
  • amino acids with aromatic side chains such as tyrosine, phenylalanine, tryptophan, histidine.
  • amino acid residues in the CDR regions of an antibody of the invention may be substituted by other amino acid residues from the same side chain family and allow the altered antibody to retain function using the functional assay methods described herein. carry out testing. Preferably, conservative modifications do not exceed 1 or 2 in number.
  • substantially homology means that two polypeptides, or specified sequences thereof, when optimally aligned and compared (with appropriate insertions or deletions of nucleotides), share at least about 80% of the amino acids, usually at least about 90% to 95%, and more preferably at least about 98% to 99.5% of the amino acids are identical.
  • the comparison of sequences and the determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.
  • sequence variants of the antibody or functional fragment thereof are all considered to be included in the protection scope of the present invention.
  • Amino acids with similar properties are substituted as in the variable region.
  • the sequence of the variant according to the invention may have at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity (or homology) with the reference sequence.
  • Sequence identity according to the invention can be measured using sequence analysis software. For example the computer program BLAST, especially BLASTP or TBLASTN, using default parameters.
  • the amino acid sequences mentioned in the present invention are all shown from the N-terminus to the C-terminus.
  • antibodies of the invention may be full-length (e.g., IgG1 or IgG4 antibodies) or may comprise only an antigen-binding portion (e.g., Fab, F(ab')2 or scFv fragments), or may be modified to affect functionality.
  • the invention includes anti-B7H6 antibodies with modified glycosylation patterns. In some applications, it may be useful to modify antibodies to remove undesired glycosylation sites, or the absence of fucose moieties on the oligosaccharide chain, for example to enhance antibody-dependent cellular cytotoxicity (ADCC) function. In other applications, galactosylation modifications can be made to alter complement dependent cytotoxicity (CDC).
  • ADCC antibody-dependent cellular cytotoxicity
  • the term "functional fragment” as used herein especially refers to antibody fragments such as Fv, scFv (sc refers to single chain), Fab, F(ab')2, Fab', scFv-Fc fragments or diabodies, or Any fragment that should be able to increase the half-life by chemical modification, such as the addition of poly(alkylene) glycols, such as polyethylene glycol (“pegylation, PEGylation”), or by incorporation into liposomes ”) (pegylated fragments known as Fv-PEG, scFv-PEG, Fab-PEG, F(ab')2-PEG or Fab'-PEG) ("PEG” is polyethylene glycol), so Said fragment has B7H6 binding activity.
  • poly(alkylene) glycols such as polyethylene glycol (“pegylation, PEGylation")
  • the functional fragment will consist of or comprise a partial sequence of the heavy chain variable region or light chain variable region of the antibody from which it is derived, said partial sequence being sufficient to retain the same binding specificity and sufficient affinity as the antibody from which it is derived , for B7H6, preferably at least equal to 1/100 of the affinity of its source antibody, and in a more preferred manner at least equal to 1/10.
  • Such functional fragments will comprise a minimum of 5 amino acids, preferably 10, 15, 25, 50 and 100 contiguous amino acids of the antibody sequence from which they are derived.
  • the present invention provides an antibody capable of binding to B7H6 or an antigen-binding fragment thereof, characterized in that the antibody includes heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3, and light chain CDR1, light chain CDR2 and Light chain CDR3.
  • the antibody is capable of binding to B7H6, especially the amino acid sequence shown in SEQ ID NO: 21.
  • the antibody in order to further improve the biological acceptability of the antibody, can also be humanized, that is, the antibody is a chimeric antibody or a humanized antibody.
  • chimeric antibody refers to the use of recombinant DNA technology to replace the amino acid sequence of the constant region of a monoclonal antibody from one species (such as a mouse) with the constant region of an antibody from another species (such as a human). Antibody.
  • humanized antibody refers to the use of recombinant DNA technology to replace all non-CDR (Fv framework region (FR)) amino acid sequences of the constant region and variable region of a monoclonal antibody from a species (such as a mouse) with A recombinant antibody obtained from the non-CDR amino acid sequences of the constant and variable regions of an antibody from another species (such as a human). That is, when the constant region of an antibody is humanized, it is called a chimeric antibody, and when all non-CDR amino acid sequences of the constant region and variable region are humanized, it is called a humanized antibody.
  • the method of humanization can be carried out with reference to the conventional antibody engineering technology, and will not be repeated here.
  • the sequence of the heavy chain variable region of the humanized antibody provided by the present invention is shown in SEQ ID NO: 17, the sequence of the light chain variable region is shown in SEQ ID NO: 18; or, the sequence of the heavy chain variable region As shown in SEQ ID NO:19, the sequence of the light chain variable region is shown in SEQ ID NO:20.
  • the immunoconjugate provided by the present invention contains a therapeutic agent and an antibody or antigen-binding fragment thereof as described above coupled to the therapeutic agent.
  • the way in which the antibody or antigen-binding fragment thereof is coupled to the therapeutic agent can be a conventional way.
  • composition provided by the present invention contains the aforementioned antibody or antigen-binding fragment thereof, and/or the above-mentioned immunoconjugate, and a pharmaceutically acceptable carrier.
  • the composition includes temporally and/or spatially separated combinations as long as they are capable of acting together to achieve the purpose of the present invention.
  • the ingredients contained in the composition may be administered to the subject as a whole, or separately.
  • the ingredients contained in the composition may be administered to the subject simultaneously or sequentially.
  • composition is capable of being administered to a subject without adverse physiological effects that would preclude administration of the composition.
  • pharmaceutically acceptable carrier refers to a carrier useful in the preparation of a generally safe, non-toxic, and desirable pharmaceutical composition.
  • examples of such carriers or diluents include, but are not limited to: water, saline, forest Grignard solution, dextrose, mannitol, dextrose, lactose, starch, magnesium stearate, cellulose, magnesium carbonate, 0.3% glycerin, hyaluronic acid, ethanol, polyalkylene glycols such as polypropylene glycol, triglycerides Esters, 5% human serum albumin, liposomes and non-aqueous vehicles such as fixed oils can also be used.
  • compositions of the invention may also be administered in combination with each other, or with one or more other therapeutic compounds, for example, with a chemotherapeutic agent. Accordingly, the composition may also contain a chemotherapeutic agent.
  • a chemotherapeutic agent for example, a chemotherapeutic agent.
  • the pro-binding fragment, or immunoconjugate can also be combined with a second therapeutic agent, exemplary agents of which include, but are not limited to, other agents that inhibit B7H6 activity (including other antibodies or antigen-binding fragments thereof, peptide inhibitory agents, small molecule antagonists, etc.) and/or agents that interfere with B7H6 upstream or downstream signal transduction.
  • exemplary agents of which include, but are not limited to, other agents that inhibit B7H6 activity (including other antibodies or antigen-binding fragments thereof, peptide inhibitory agents, small molecule antagonists, etc.) and/or agents that interfere with B7H6 upstream or downstream signal transduction.
  • the antibody or antigen-binding fragment thereof is administered in an effective amount, that is, an amount sufficient to achieve the desired therapeutic and/or prophylactic effect, e.g., an amount that causes prevention or alleviation of symptoms associated with the disease being treated, the A disease such as a disease associated with B7H6.
  • the effective amount of the composition administered to a subject will depend on the type and severity of the disease, and on individual characteristics such as general health, age, sex, body weight, and tolerance to drugs; Depending on the severity and type of the disease, those skilled in the art will be able to determine the appropriate dosage based on these factors and the like.
  • the kit for detecting B7H6 in a sample provided by the present invention contains the above-mentioned antibody or antigen-binding fragment thereof.
  • the sample can be a patient suffering from a B7H6-mediated disease (especially transplant rejection, autoimmune disease, infectious disease or cancer patient, more preferably a patient suffering from lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer , colon cancer, breast cancer, glioma, renal cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer).
  • the kit may also include conventional reagents for detecting B7H6, such as coating solution and the like.
  • the present invention also provides the use of the above-mentioned antibody or antigen-binding fragment thereof in the preparation of a reagent for detecting B7H6 in a sample.
  • the sample can be the tissue of a patient suffering from a B7H6-mediated disease, which will not be repeated here.
  • the antibody or antigen-binding fragment thereof of the present invention has good affinity with B7H6, and can effectively detect B7H6 in a sample.
  • the present invention also provides the above-mentioned antibody or its antigen-binding fragment, immunoconjugate, composition, nucleic acid, recombinant vector or transformant or recombinant cell in the preparation of drugs for preventing and/or treating B7H6-mediated diseases the use of.
  • the B7H6-mediated disease is transplant rejection, autoimmune disease, infectious disease or cancer.
  • the cancer is a B7H6 expressing cancer.
  • the cancer is lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophagus cancer, oral squamous cell carcinoma and head and neck cancer at least one of the cancers.
  • the infectious disease includes but not limited to HIV virus infection and/or hepatitis B virus infection.
  • the present invention relates to a medicament, which includes the aforementioned antibody or its antigen-binding fragment, immunoconjugate, composition, nucleic acid, recombinant vector or transformant or recombinant cell.
  • the above-mentioned medicine may include at least one of the following additional technical features:
  • the drug includes a pharmaceutically acceptable carrier and an effective amount of the antibody or its antigen-binding fragment, immunoconjugate, composition, nucleic acid, recombinant vector or transformant or recombinant cell .
  • the present invention also relates to a method for preventing and/or treating B7H6-mediated diseases (as described above), the method comprising: administering an effective amount of an antibody or antigen-binding fragment thereof, an immunoconjugate, or a composition of the present invention , a recombinant cell, a nucleic acid, and a drug are administered to a patient.
  • the administration method may be oral administration, nasal administration, intradermal administration, subcutaneous administration, intramuscular administration, intravenous administration or intraperitoneal administration.
  • the antibody or antigen-binding fragment thereof can effectively bind to B7H6, thereby promoting the interaction between B7H6 and NKp30, and strengthening the anti-cancer function of NK cells.
  • the antibody or its antigen-binding fragment, and the substance capable of expressing the antibody or its antigen-binding fragment under suitable conditions, or the substance comprising the antibody or its antigen-binding fragment can effectively prevent and/or
  • the methods according to the embodiments of the present invention can effectively prevent and/or treat B7H6-mediated diseases.
  • the above method may also include at least one of the following additional technical features:
  • the B7H6-mediated disease is cancer or an infectious disease.
  • the cancer is lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous At least one of cell carcinoma and head and neck cancer.
  • the "patient” or “subject” referred to in the present invention generally refers to mammals, such as primates and/or rodents, especially humans or mice.
  • the present invention also provides (isolated) nucleic acids encoding the above-mentioned antibodies or antigen-binding fragments thereof, as well as recombinant vectors and transformants comprising the nucleic acids.
  • the nucleic acid is preferably an expression cassette obtained by genetic engineering.
  • Recombinant vectors can refer to cloning vectors or expression vectors, which can be obtained by operably linking the nucleic acid with commercially available vectors (such as plasmids or viral vectors). Commonly used plasmids include pSeTag2, PEE14, pMH3, etc.
  • the expression vector of the present invention may contain DNA sequences encoding the heavy chain variable region, light chain variable region and/or constant region of the antibody. However, it is also possible to construct two expression vectors separately, one containing the heavy chain variable region and constant region, and the other containing the light chain variable region and constant region, and transfect mammalian cells together.
  • the expression vector further contains a promoter, a DNA sequence encoding a secretion signal peptide, and at least one drug resistance gene for screening.
  • the host cell of the present invention may be a prokaryotic host cell, a eukaryotic host cell or a phage.
  • the prokaryotic host cell may be Escherichia coli, Bacillus subtilis, Streptomyces or Proteus mirabilis, etc.
  • the eukaryotic host cells may include fungi such as Pichia pastoris, Saccharomyces cerevisiae, fission yeast, Trichoderma, insect cells such as armyworm, plant cells such as tobacco, BHK cells, CHO cells, COS cells, bone marrow cells, etc. Mammalian cells such as tumor cells.
  • the host cells of the present invention are preferably mammalian cells, more preferably BHK cells, CHO cells, NSO cells or COS cells.
  • the present invention relates to a recombinant cell carrying the aforementioned nucleic acid, recombinant vector or transformant, or antibody or antigen-binding fragment.
  • the recombinant cells are obtained by transfecting or transforming the expression vector.
  • the recombinant cells can efficiently express the above-mentioned antibody under suitable conditions, and the antibody or antigen-binding fragment thereof can effectively bind to B7H6, and further, the antibody or antigen-binding fragment has good preventive And/or the effect of treating B7H6-mediated diseases.
  • the recombinant cells of the present invention are not particularly limited, and may be prokaryotic cells, eukaryotic cells or phages.
  • the prokaryotic cells may be Escherichia coli, Bacillus subtilis, Streptomyces or Proteus mirabilis, etc.
  • the eukaryotic cells can be fungi including Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces, Trichoderma, insect cells such as armyworm, plant cells such as tobacco, BHK cells, CHO cells, COS cells, myeloma cells, etc. cells and other mammalian cells.
  • the recombinant cells of the present invention are preferably mammalian cells, including BHK cells, CHO cells, NSO cells or COS cells, and do not include animal germ cells, fertilized eggs or embryonic stem cells.
  • suitable conditions refer to the conditions suitable for the expression of the antibody or antigen-binding fragment thereof described in the present application.
  • conditions suitable for expression of antibodies or antigen-binding fragments include, but are not limited to, suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy host cell states, suitable host cell densities, suitable Cell culture environment, suitable cell culture time.
  • suitable conditions are not particularly limited, and those skilled in the art can optimize the most suitable conditions for the expression of the antibody or antigen-binding fragment thereof according to the specific environment of the laboratory.
  • the present invention also relates to the use of the aforementioned antibodies or antigen-binding fragments thereof, immunoconjugates, compositions, drugs, nucleic acids, recombinant vectors or transformants or recombinant cells in the treatment and/or prevention of B7H6-mediated diseases.
  • the antibody or its antigen-binding fragment can effectively bind to B7H6, thereby promoting the interaction between B7H6 and NKp30, and strengthening the anti-cancer function of NK cells. Therefore, the antibody or its antigen-binding fragment can be used in The substances obtained by expressing the antibody or its antigen-binding fragment under appropriate conditions can effectively prevent and/or treat diseases mediated by B7H6.
  • the above-mentioned use in the treatment and/or prevention of B7H6-mediated diseases may also include at least one of the following additional technical features:
  • the B7H6-mediated disease is cancer or an infectious disease.
  • the cancer is lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous At least one of cell carcinoma and head and neck cancer.
  • the present invention provides a method for diagnosing whether a subject suffers from a B7H6-mediated disease.
  • the method includes using at least one of the following to detect B7H6 in the sample to be tested: 1) the aforementioned antibody or an antigen-binding fragment thereof; 2) the aforementioned nucleic acid; 3 ) the aforementioned recombinant vector or transformant; and 4) the aforementioned recombinant cell, based on the detection result of B7H6, determine the content of B7H6 in the sample to be tested.
  • the antibodies or antigen-binding fragments of the embodiments of the present invention can effectively bind to B7H6.
  • the antibodies or antigen-binding fragments can be used to detect B7H6, and B7H6 mediates various diseases. Therefore, according to the subject
  • the level of B7H6 contained in the source biological sample can determine whether the subject suffers from a B7H6-mediated disease.
  • the above-mentioned substances can also be used to monitor the content of B7H6 in the subject's test sample, that is, the above-mentioned substances can also be used for disease staging of subjects suffering from B7H6-mediated diseases, and can also be used for B7H6-mediated diseases. prognostic assessment of the disease.
  • the above method may further include at least one of the following additional technical features:
  • the content of B7H6 in the test sample is not lower than the minimum standard for disease, which is an indication that the test sample is derived from a patient suffering from a B7H6-mediated disease.
  • the minimum standard value can be determined by comparative analysis and verification of the B7H6 content in a large number of individuals suffering from the B7H6-mediated disease and a large number of healthy individuals in the samples to be tested.
  • the B7H6-mediated disease is cancer or an infectious disease.
  • the cancer is lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous At least one of cell carcinoma and head and neck cancer.
  • the sample to be tested includes at least one of the following: tissue, cell, blood, serum, sweat, feces and urine.
  • the present invention proposes the use of at least one of the following in diagnosing whether a subject suffers from a B7H6-mediated disease: 1) the aforementioned antibody or an antigen-binding fragment thereof; 2) the aforementioned said nucleic acid; 3) said recombinant vector or transformant; and 4) said said recombinant cell.
  • the antibodies or antigen-binding fragments of the embodiments of the present invention can effectively bind to B7H6. Therefore, the antibodies or antigen-binding fragments can be used to detect B7H6, and B7H6 mediates various diseases. Therefore, according to the subject The level of B7H6 contained in the source biological sample can determine whether the subject suffers from a B7H6-mediated disease.
  • the above use may further include at least one of the following additional technical features:
  • the B7H6-mediated disease is cancer or an infectious disease.
  • the cancer is lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous At least one of cell carcinoma and head and neck cancer.
  • nucleic acid encoding the heavy chain and/or light chain of the antibody of the present invention is within the scope of the present invention. According to the amino acid sequence of the heavy chain and/or light chain, those skilled in the art can easily obtain the corresponding nucleic acid sequence, as shown in Table 2 shown.
  • B7H6-Fc recombinant B7H6 extracellular region Fc fusion protein, amino acid sequence shown in SEQ ID NO: 22
  • mice were immunized three times with purified antigen and complete Freund's adjuvant, and the immune response was detected after bloodletting from the tail vein.
  • the serum was screened by ELISA and flow cytometry, and mice with anti-human B7H6 immunoglobulin were obtained.
  • mice with anti-human B7H6 immunoglobulin were obtained.
  • the splenocytes from the mouse with the highest anti-B7H6 immunoglobulin were fused with the mouse myeloma cell SP2/0 cell (ATCC number CRL-1581).
  • the fused hybridoma cells were screened for antibodies to obtain mouse monoclonal antibodies.
  • the total number of candidate hybridoma cells was cultivated to 106, and the cells were collected by centrifugation at 800rpm for 10 minutes, and total RNA was extracted with the Trizol kit (Invitrogen); using the total RNA as a template, reverse transcription was used to synthesize a cDNA library (Invitrogen), and cDNA was used as a template PCR amplifies the corresponding variable region nucleic acid sequences of the hybridoma cells.
  • the primer sequences used in the PCR amplification reaction are complementary to the first framework region or signal peptide region of the antibody variable region and the constant region (Larrick, J.W., et al., (1990) Scand.J.Immunol., 32, 121- 128 and Coloma, J.J. et al., (1991) BioTechniques, 11, 152-156).
  • B7H6 extracellular region Fc fusion protein B7H6-Fc
  • B7H6-Fc B7H6 extracellular region Fc fusion protein
  • the B7H6-Fc fusion protein (amino acid sequence shown in SEQ ID NO: 22) was diluted to 1 ⁇ g/mL with PBS buffer, added to a 96-well plate at a volume of 100 ⁇ L/well, and left overnight at 4°C. Aspirate the PBS buffer in the 96-well plate, wash the plate 6 times with PBST (pH7.2 PBS containing 0.1% Tween 20) buffer, add 200 ⁇ L/well PBS/10% BSA, and incubate at 37°C for 2 hours to block.
  • PBST pH7.2 PBS containing 0.1% Tween 20
  • the B7H6 protein (HL60-B7H6, SEQ ID NO:21; SEQ ID NO:54) was overexpressed in HL60 cells (ATCC number CCL-240), and the expression vector For pLVX-EF1a-B7H6-IRES-ZsGreen, the strength of the signal after adding the antibody is used to judge the binding characteristics of the antibody and B7H6.
  • HEK293T cells were plated in a six-well plate at 5 ⁇ 105 cells/well, and cultured overnight in DMEM medium without double antibodies. The medium was discarded before transfection, and 1 mL of fresh DMEM medium without double antibody was added.
  • the coding sequence (SEQ ID NO:54) of the B7H6 protein (SEQ ID NO:21) was inserted between the restriction site EcoRI and BamHI of the pLVX-EF1a-B7H6-IRES-ZsGreen (pLVX-EF1a-IRES-ZsGreen1 vector , pMD2G, and psPAX2 vectors (3 ⁇ g in total) were added to 200 ⁇ l of serum-free DMEM medium at a ratio of 2:1:1, and 12 ⁇ g of polyetherimide (PEI, Polysciences Co., Ltd.) was added. After mixing, let stand for 16 minutes, and then All the liquid was added to the six-well plate covered with HEK293T cells.
  • PEI polyetherimide
  • the cells were resuspended in 100 ⁇ l/tube of PBS, 0.1 ⁇ L/tube of Alexa-647-labeled goat anti-mouse antibody secondary antibody (Invitrogen) was added thereto, and incubated at 4°C in the dark for 30 min. Wash twice with PBS, centrifuge and discard the supernatant. The cells were resuspended in 200 ⁇ L/tube of PBS, and detected by flow cytometry.
  • Alexa-647-labeled goat anti-mouse antibody secondary antibody Invitrogen
  • the humanized template that best matches its non-CDR region.
  • the CDR region of the murine antibody is grafted onto the selected humanized template, and the CDR region of the humanized template is replaced to obtain a humanized antibody. Then, based on the three-dimensional structure of the murine antibody, the buried residues, the residues that directly interact with the CDR region, and the residues that have an important impact on the conformation of VL and VH are back-mutated to obtain humanization.
  • sequence of the heavy chain variable region of the humanized B7H6 antibody 12F5 is shown in SEQ ID NO: 17, and the sequence of the light chain variable region is shown in SEQ ID NO: 18, or, the humanized B7H6 antibody 12G4 heavy
  • sequence of the chain variable region is shown in SEQ ID NO:19
  • sequence of the light chain variable region is shown in SEQ ID NO:20.
  • B7H6 extracellular region Fc fusion protein B7H6-Fc
  • B7H6-Fc B7H6 extracellular region Fc fusion protein
  • the B7H6-Fc fusion protein (amino acid sequence shown in SEQ ID NO: 22) was diluted to 1 ⁇ g/mL with PBS buffer, added to a 96-well plate at a volume of 100 ⁇ L/well, and left overnight at 4°C. Aspirate the PBS buffer in the 96-well plate, wash the plate 6 times with PBST (pH7.2 PBS containing 0.1% Tween 20) buffer, add 200 ⁇ L/well PBS/10% BSA, and incubate at 37°C for 2 hours to block.
  • PBST pH7.2 PBS containing 0.1% Tween 20
  • B7H6 protein HL60-B7H6
  • ATCC number CCL-240 ATCC number CCL-240
  • Dilute HL60-B7H6 cells to 2 ⁇ 106/mL with PBS add 100 ⁇ L/tube to a 1.5 mL EP tube, add 10 ⁇ L/tube mouse serum to it, and block at 4°C for 30 min.
  • Monkey B7H6 protein (CHO-K1-cyno-B7H6) was overexpressed in CHO-K1 cells (ATCC number CCL-240), and the signal after antibody addition The strength of is used to judge the binding characteristics of the antibody and monkey B7H6.
  • HEK293T cells were plated in a six-well plate at 5 ⁇ 105 cells/well, and cultured overnight in DMEM medium without double antibodies. The medium was discarded before transfection, and 1 mL of fresh DMEM medium without double antibody was added.
  • the coding sequence (SEQ ID NO:57) of the monkey B7H6 protein (SEQ ID NO:24) was inserted between the restriction site EcoRI and BamHI of the pLVX-EF1a-cynoB7H6-IRES-ZsGreen (pLVX-EF1a-IRES-ZsGreen1 vector) ), pMD2G, and psPAX2 vectors (3 ⁇ g in total) were added to 200 ⁇ L serum-free DMEM medium according to the ratio of 2:1:1, and 12 ⁇ g polyetherimide (PEI, Polysciences Co., Ltd.) was added. After mixing, let it stand for 16 min, and then All the liquid was added to a six-well plate covered with HEK293T cells.
  • PEI polyetherimide
  • Virus supernatant is all added in the 6 well plate that contains 1 * 104 CHO-K1 cell, adds the polybrene (Sigma) of final concentration 4 ⁇ g/ml, cultivates 12h. Discard supernatant then, Add fresh complete RPMI1640 medium. The resulting cells are CHO-K1-cyno B7H6 cells.
  • CHO-K1-cynoB7H6 cells Dilute CHO-K1-cynoB7H6 cells to 2 ⁇ 106/mL with PBS, add 100 ⁇ L/tube to a 1.5 mLEP tube, add 10 ⁇ L/tube mouse serum to it, and block at 4°C for 30 min. Add 1 ⁇ g/tube of humanized B7H6 antibody and incubate at 4°C for 30 min. Add 1mL PBS to the EP tube, centrifuge at 3500rpm ⁇ 5min at 4°C, discard the supernatant, and wash again with PBS.
  • Example 8 ELISA binding experiment of humanized B7H6 antibody
  • ELISA experiments were used to examine the binding properties of humanized B7H6 antibodies.
  • the monkey B7H6 extracellular region Fc fusion protein (cynoB7H6-Fc) was coated on a 96-well plate, and the strength of the signal after the antibody was added was used to determine the binding characteristics of the antibody and monkey B7H6.
  • the cynoB7H6-Fc fusion protein (amino acid sequence shown in SEQ ID NO: 23) was diluted to 1 ⁇ g/mL with PBS buffer, added to a 96-well plate at a volume of 100 ⁇ L/well, and left overnight at 4°C. Aspirate the PBS buffer in the 96-well plate, wash the plate 6 times with PBST (pH7.2 PBS containing 0.1% Tween 20) buffer, add 200 ⁇ L/well PBS/10% BSA, and incubate at 37°C for 2 h to block.
  • PBST pH7.2 PBS containing 0.1% Tween 20
  • the Biacore method is recognized as a detection method for objectively detecting the mutual affinity and kinetics of proteins, and the B7H6 antibody of the present invention is analyzed by Biacore T200 to characterize the affinity and binding kinetics.
  • the B7H6 extracellular fragment Fc fusion protein (B7H6-Fc) was covalently linked to the CM5(GE) chip by standard amino coupling method.
  • a series of concentration gradients of the B7H6 antibody diluted in PBS was then injected with each cycle and regenerated with 10 mM NaOH solution after injection.
  • Antigen-antibody binding kinetics were followed for 3 minutes and dissociation kinetics were followed for 10 minutes, and the resulting data were analyzed using GE's BIAevaluation software with a 1:1 (Langmuir) binding model.
  • the KD value of mouse 12F5 determined by this method is 2.2nM
  • the KD value of mouse 12G4 is 0.15nM.
  • Example 10 Antibody promotes the screening of the ability of B7H6 to bind NKp30
  • the B7H6 antibody promotes the signaling pathway between B7H6 and its receptor NKp30 by binding to the extracellular region of B7H6.
  • Flow cytometry experiments were used to detect the enhancement of the binding of the B7H6 antibody to the receptor NKp30.
  • HL60-B7H6 cells Dilute HL60-B7H6 cells (same as above) with PBS to 2 ⁇ 106/ml, add 100 ⁇ L/tube to a 1.5 mL EP tube, add 10 ⁇ L/tube mouse serum to it, and block at 4°C for 30 min.
  • B7H6 antibody and incubate at 4°C for 30min.
  • Complement-dependent cytotoxicity assay used to detect the effect of B7H6 antibody on tumor cell killing.
  • the tumor cells used are HL60-B7H6 cells.
  • Tumor cells were resuspended in serum-free RPMI-1640 medium and counted. Dilute to 4 ⁇ 105/mL with complete RPMI-1640 medium. Add the diluted cells to a 96-well round bottom plate at a volume of 25 ⁇ L/well
  • the in vivo drug efficacy experiment is used to detect the anti-cancer function of nude mice promoted by B7H6 antibody.
  • the tumor cells used were acute myeloid leukemia U-937 cells (ATCC number CRL-1953.2).
  • mice were randomly divided into groups.
  • mice were intraperitoneally injected with the antibody, 1 mg per mouse.
  • the antibody obtained in the present invention can bind human and monkey B7H6; can promote the interaction between B7H6 and NKp30; and can promote anti-cancer in mice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了B7H6抗体及其应用。所述抗体包括重链CDR1、重链CDR2和重链CDR3，以及轻链CDR1、轻链CDR2和轻链CDR3。本发明的抗体能够与B7H6结合，促进B7H6与NK细胞活化性受体NKp30的结合，以及具有抗癌功能。

Description

B7H6抗体及其应用
优先权信息
本申请请求2021年12月07日向中国国家知识产权局提交的、专利申请号为202111485380.9的专利申请的优先权和权益，并且通过参照将其全文并入此处。
技术领域
本发明涉及抗体领域，具体地，涉及一种能够结合B7H6的抗体或其抗原结合片段及用途。
背景技术
NK细胞是机体中非常重要的一种固有样淋巴细胞，在抗病毒、抗肿瘤中发挥重要作用。NK细胞表面表达多种活化性受体，包括NKp30、NKG2D等，识别并结合肿瘤细胞表面表达的配体，这些配体都是由自身基因编码的，在细胞恶性转化(肿瘤)等条件下表达在细胞表面。
NKp30是种重要的NK细胞活化性受体，与其配体结合后，传递活化信号，促进NK细胞杀伤肿瘤。B7H6是已知的唯一一种膜蛋白形式表达的NKp30配体，B7-H6在多种肿瘤组织如黑色素瘤、肝癌等高表达，在正常组织中不表达，具有肿瘤特异性。
肿瘤微环境中TGF-β等细胞因子下调NK细胞表面NKp30表达，造成NK细胞无法利用NKp30-B7H6相互作用精准识别、灭杀肿瘤，进而造成肿瘤免疫逃逸。因而提供一种靶向B7H6的治疗性抗体药物十分必要。
发明内容
本发明的目的是克服现有技术的不足，提供一种能够与人及猴B7H6结合、并促进B7H6与NKp30结合的B7H6抗体及其用途。
本发明提供的抗体通过促进B7H6与NKp30的结合，促进NK细胞的抗癌功能。
在一方面，本发明提供了一种能够结合B7H6的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包括重链CDR1、重链CDR2和重链CDR3，以及轻链CDR1、轻链CDR2和轻链CDR3，其中，
所述重链CDR1包含选自SEQ ID NO:1、SEQ ID NO:7所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一；
所述重链CDR2包含选自SEQ ID NO:2、SEQ ID NO:8所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一；
所述重链CDR3包含选自SEQ ID NO:3、SEQ ID NO:9所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一；
所述轻链CDR1包含选自SEQ ID NO:4、SEQ ID NO:10所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一；
所述轻链CDR2包含自SEQ ID NO:5、SEQ ID NO:11所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一；以及
所述轻链CDR3含选自SEQ ID NO:6、SEQ ID NO:12所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一。
在某些实施例中，所述的抗体或其抗原结合片段包含：
1)具有SEQ ID NO:1所示的氨基酸序列的重链CDR1，具有SEQ ID NO:2所示的氨基酸序列的重链CDR2，具有SEQ ID NO:3所示的氨基酸序列的重链CDR3，具有SEQ ID NO:4所示的氨基酸序列的轻链CDR1，具有SEQ ID NO:5所示的氨基酸序列的轻链CDR2，具有SEQ ID NO:6所示的氨基酸序列的轻链CDR3：或
2)具有SEQ ID NO:7所示的氨基酸序列的重链CDR1，具有SEQ ID NO:8所示的氨基酸序列的重链CDR2，具有SEQ ID NO:9所示的氨基酸序列的重链CDR3，具有SEQ ID NO:10所示的氨基酸序列的轻链CDR1，具有SEQ ID NO:11所示的氨基酸序列的轻链CDR2，具有SEQ ID NO:12所示的氨基酸序列的轻链CDR3。
在某些实施例中，所述抗体或其抗原结合片段包括重链可变区和轻链可变区，(i)所述重链可变区包含SEQ ID NO:13、SEQ ID NO:15、SEQ ID NO:17、SEQ ID NO:19所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一至少80％同源性的氨基酸序列；和/或，(ii)所述轻链可变区包含SEQ ID NO:14、SEQ ID NO:16、SEQ ID NO:18、SEQ ID NO:20所示的氨基酸序列及其保修修饰形式的氨基酸序列至少之一至少80％同源性的氨基酸序列。
在某些实施例中，所述重链可变区包含与选自(i)中的重链可变区至少90％，至少95％，至少96％，至少97％，至少98％，至少99％或者100％同源性的氨基酸序列；所述轻链可变区包含与选自(ii)中的轻链可变区至少90％，至少95％，至少96％，至少97％，至少98％，至少99％或者100％同源性的氨基酸序列。
在某些实施例中，所述抗体或其抗原结合片段包括：
1)所述重链可变区如SEQ ID NO:13所示的氨基酸序列，以及所述轻链可变区如SEQ ID NO:14所示的氨基酸序列；
2)所述重链可变区如SEQ ID NO:15所示的氨基酸序列，以及所述轻链可变区如SEQ ID NO:16所示的氨基酸序列；
3)所述重链可变区如SEQ ID NO:17所示的氨基酸序列，以及所述轻链可变区如SEQ ID NO:18所示的氨基酸序列；或
4)所述重链可变区如SEQ ID NO:19所示的氨基酸序列，以及所述轻链可变区如SEQ ID NO:20所示的氨基酸序列。
在某些实施例中，所述抗体或其抗原结合片段包括：
1)所述重链如SEQ ID NO:26所示的氨基酸序列，以及所述轻链如SEQ ID NO:27所示的氨基酸序列；
2)所述重链如SEQ ID NO:28所示的氨基酸序列，以及所述轻链如SEQ ID NO:29所示的氨基酸序列；
3)所述重链如SEQ ID NO:30所示的氨基酸序列，以及所述轻链如SEQ ID NO:31所示的氨基酸序列；或
4)所述重链如SEQ ID NO:32所示的氨基酸序列，以及所述轻链如SEQ ID NO:33所示的氨基酸序列。
在某些实施例中，所述的分离的抗体是IgG1、IgG2或IgG4。
在某些实施例中，所述抗体为单克隆抗体、鼠源抗体、嵌合抗体、人源化抗体人改造抗体、人抗体、Fv、单链抗体(scFv)、Fab、Fab’，Fab’-SH或者F(ab’) 2。
在某些实施例中，所述抗体或其抗原结合片段能够结合SEQ ID NO:21所示的氨基酸序列。
在另一方面，本发明提供了一种免疫缀合物，该免疫缀合物含有治疗剂以及与治疗剂偶联的上述的抗体或其抗原结合片段。
在又一方面，本发明提供了一种组合物，其中，所述组合物含有上述的抗体或其抗原结合片段、和/或上述的免疫缀合物、以及药学上可接受的载体。
在再一方面，本发明提供了一种用于检测样品中B7H6的试剂盒，该试剂盒含有上述抗体或其抗原结合片段。
在又一方面，本发明提供了上述的抗体或其抗原结合片段在制备用于检测样品中B7H6的试剂中的用途。
在再一方面，本发明提供了上述的抗体或其抗原结合片段在制备用于预防和/或治疗B7H6介导的疾病的药物中的用途，所述B7H6介导的疾病为癌症或感染性疾病，
任选地，所述癌症为肺癌，肝癌，卵巢癌，宫颈癌，皮肤癌，膀胱癌，结肠癌，乳腺癌，神经胶质瘤，肾癌，胃癌，食道癌，口腔鳞状细胞癌和头颈癌中的至少一种。
在又一方面，本发明提供了一种核酸，其包含编码上述的抗体或其抗原结合片段的核酸。
在再一方面，本发明提供了一种重组载体或转化子，其含有上述的核酸。
在一个方面，本发明提供了一种重组细胞，所述重组细胞携带前面所述的核酸、表达载体或转化子 或表达前面所述的抗体或其抗原结合片段。
在另一个方面，本发明提供了一种药物，包括前面所述的抗体或其抗原结合片段、免疫缀合物、组合物、药物、核酸、重组载体或转化子或重组细胞。
在又一方面，本发明提供了前面所述的抗体或其抗原结合片段、免疫缀合物、组合物、药物、核酸、重组载体或转化子或重组细胞在治疗和/或预防B7H6介导的疾病中的用途。如前所述，所述抗体或其抗原结合片段能够有效与B7H6进行结合，进而促进B7H6与NKp30的相互作用，加强NK细胞抗癌功能，因此，所述抗体或其抗原结合片段，以及能够在合适的条件下表达获得所述抗体或其抗原结合片段的物质均能够有效预防和/或治疗B7H6介导的疾病。
在另一方面，本发明提出了一种治疗和/或预防B7H6介导的疾病的方法。根据本发明的实施例，所述方法包括向受试者施用以下中的至少之一：1)前面述的抗体或其抗原结合片段；2)前面所述的免疫缀合物；3)前面所述的组合物；4)前面所述的药物；5)前面所述的核酸；6)前面所述的重组载体或转化子；和7)前面所述的重组细胞。如前所述，所述抗体或其抗原结合片段能够有效与B7H6进行结合，进而促进B7H6与NKp30的相互作用，加强NK细胞抗癌功能，因此，所述抗体或其抗原结合片段，以及能够在合适的条件下表达获得所述抗体或其抗原结合片段的物质，或者包含所述抗体或其抗原结合片段的物质均能够有效预防和/或治疗B7H6介导的疾病，根据本发明实施例的方法能够有效预防和/或治疗B7H6介导的疾病。
在又一方面，本发明提供了一种诊断受试者是否患有B7H6介导的疾病的方法。根据本发明的实施例，所述方法包括使用下列中的至少之一对待测样品中的B7H6进行检测：1)前面所述的抗体或其抗原结合片段；2)前面所述的核酸；3)前面所述的重组载体或转化子；和4)前面所述的重组细胞，基于所述B7H6的检测结果，确定所述待测样品中B7H6的含量。如前所述，本发明实施例的抗体或抗原结合片段能够有效与B7H6进行结合，因此，所述抗体或抗原结合片段可用于检测B7H6，而B7H6介导多种疾病，因此，根据受试者来源的生物样品中含有的所述B7H6的水平可以判断所述受试者是否患有B7H6介导的疾病。此外，还可以利用上述物质监控受试者待测样品中的B7H6的含量，即上述物质也可以用于对患有B7H6介导的疾病的受试者进行疾病分期，也可以用于B7H6介导的疾病的预后评估。
在再一方面，本发明提供了下列中的至少之一在诊断受试者是否患有B7H6介导的疾病中的用途：1)前面述的抗体或其抗原结合片段；2)前面所述的核酸；3)前面所述的重组载体或转化子；和4)前面所述的重组细胞。如前所述，本发明实施例的抗体或抗原结合片段能够有效与B7H6进行结合，因此，所述抗体或抗原结合片段可用于检测B7H6，而B7H6介导多种疾病，因此，根据受试者来源的生物样品中含有的所述B7H6的水平可以判断所述受试者是否患有B7H6介导的疾病。
通过上述技术方案，本发明提供了能够结合人及猴B7H6的抗B7H6抗体或其抗原结合片段。本发明的抗体或其抗原结合片段具有以下特性的至少一种：能够结合人及猴B7H6；能够促进B7H6与NKp30的相互作用；能够促进NK细胞抗癌功能。
本发明的其它特征和优点将在随后的具体实施方式部分予以详细说明。
本发明的附加方面和优点将在下面的描述中部分给出，部分将从下面的描述中变得明显，或通过本发明的实践了解到。
附图说明
本发明的上述和/或附加的方面和优点从结合下面附图对实施例的描述中将变得明显和容易理解，其中：
附图是用来提供对本发明的进一步理解，并且构成说明书的一部分，与下面的具体实施方式一起用于解释本发明，但并不构成对本发明的限制。在附图中：
图1为根据本发明具体实施方式的鼠源B7H6抗体结合人B7H6的ELISA结果图；
图2为根据本发明具体实施方式的鼠源B7H6抗体结合HL60-B7H6细胞的结果图；
图3为根据本发明具体实施方式的人源化B7H6抗体结合人B7H6的ELISA结果图；
图4为根据本发明具体实施方式的人源化B7H6抗体结合HL60-B7H6细胞的结果图；
图5为根据本发明具体实施方式的人源化B7H6抗体结合CHO-K1-cyno B7H6细胞的结果图；
图6为根据本发明具体实施方式的人源化B7H6抗体结合猴B7H6的ELISA结果图；
图7为根据本发明具体实施方式的B7H6抗体促进受体NKp30结合的结果图；
图8为根据本发明具体实施方式的B7H6抗体介导补体依赖的细胞毒效应的结果图；
图9为根据本发明具体实施方式的B7H6抗体促进裸鼠对抗人急性髓系白血病U-937肿瘤的结果图。
具体实施方式
下面详细描述本发明的实施例，所述实施例的示例在附图中示出。下面通过参考附图描述的实施例是示例性的，旨在用于解释本发明，而不能理解为对本发明的限制。
需要说明的是，术语“第一”、“第二”仅用于描述目的，而不能理解为指示或暗示相对重要性或者隐含指明所指示的技术特征的数量。由此，限定有“第一”、“第二”的特征可以明示或者隐含地包括一个或者更多个该特征。进一步地，在本发明的描述中，除非另有说明，“多个”的含义是两个或两个以上。
以下对本发明的具体实施方式进行详细说明。应当理解的是，此处所描述的具体实施方式仅用于说明和解释本发明，并不用于限制本发明。
在本文中所披露的范围的端点和任何值都不限于该精确的范围或值，这些范围或值应当理解为包含接近这些范围或值的值。对于数值范围来说，各个范围的端点值之间、各个范围的端点值和单独的点值之间，以及单独的点值之间可以彼此组合而得到一个或多个新的数值范围，这些数值范围应被视为在本文中具体公开。
为了更容易理解本发明，以下具体定义了某些技术和科学术语。除显而易见在本文件中的它处另有明确定义，否则本文中使用的所有其它技术和科学术语都具有本发明所属领域的一般技术人员通常理解的含义。氨基酸残基的缩写是本领域中所用的指代20个常用L-氨基酸之一的标准3字母和/或1字母代码。
在本发明中，在未作相反说明的情况下，使用的术语抗原结合片段也即“抗体片段”，抗体片段通常是指抗原结合性抗体片段，可以包括完整抗体的一部分，一般是抗原结合区或可变区，抗体片段的实例包括Fab、Fab’、F(ab’)2、Fv或scFv，双抗体，线性抗体，单链抗体分子等。
术语“互补决定区”或“CDR”或“CDR序列”是指抗体中负责抗原结合的氨基酸序列，例如，通常包括：轻链可变区中23-34(L1)、50-56(L2)和89-97(L3)附近，和重链可变区中31-35B(H1)、50-65(H2)和95-102(H3)附近的氨基酸残基(Kabat等人，Sequences of Proteins of Immunological Interest，5th Ed.Public Health Service，National Institutes of Health，Bethesda，MD.(1991))；和/或来自“高变环”(例如，轻链可变区中26-32(LI)、50-52(L2)和91-96(L3)，和重链可变区中26-32(H1)、53-55(H2)和96-101(H3)附近的氨基酸残基(Chothia和Lesk J.Mol.Biol.196：901-917(1987))。
术语“保守修饰形式的氨基酸序列”指这样的氨基酸修饰，它不显著影响或改变包含该氨基酸序列的抗体的结合特性，该修饰包括氨基酸置换、增加和缺失。修饰可通过例如定点诱变和PCR介导的诱变等标准技术引入本发明的抗体中。保守氨基酸置换系其中的氨基酸残基被具有相似侧链的氨基酸残基替换的置换。在本领域中已经确定具有相似侧链的氨基酸残基家族。这些家族包括具有碱性侧链的氨基酸(如赖氨酸、精氨酸、组氨酸)，具有酸性侧链的氨基酸(如天冬氨酸、谷氨酸)，具有不带电的极性侧链的氨基酸(如甘氨酸、天冬酰胺、谷氨酰胺、丝氨酸、苏氨酸、酪氨酸、半胱氨酸、色氨酸)，具有非极性侧链的氨基酸(如丙氨酸、缬氨酸、亮氨酸、异亮氨酸、脯氨酸、苯丙氨酸、甲硫氨酸)，具有β-支化侧链的氨基酸(如苏氨酸、缬氨酸、异亮氨酸)、和具有芳香侧链的氨基酸(如酪氨酸、苯丙氨酸、色氨酸、组氨酸)。因此，本发明的抗体的CDR区中的一个或多个氨基酸残基可以被来自相同侧链家族的其他氨基酸残基替代，并且使可用此处说明的功能测定方法对经改变的抗体的保留功能进行测试。优选的是，保守修饰在数目上不超过1个或2个。
对于多肽而言，术语“实质同源性”表示，两个多肽或其指定序列在最佳比对及比较(其中适当插入或缺失核苷酸)时有至少约80％的氨基酸、通常至少约90％至95％、且更优选至少约98％至99.5％的氨基酸相同。
两条序列之间的同一性％在最佳比对序列时随这些序列所共享的相同位置数而变化(即同源性％＝相同位置数/总位置数×100)，其中最佳比对系考虑到为达成两条序列的最佳比对而需要引入的空位数及 每一空位的长度来确定。两条序列之间的序列比较及同一性百分数测定可使用数学算法来完成，如下文非限制性实施例中所述。
在不实质性影响抗体活性(保留至少95％的活性)的前提下，本领域技术人员可以对本发明的序列替换、添加和/或缺失一个或更多个(例如1、2、3、4、5、6、7、8、9或10个或更多个)氨基酸，以获得所述抗体或其功能性片段之序列的变体。它们都被视为包括在本发明保护的范围内。如在可变区将具有类似性质的氨基酸进行替换。本发明所述变体的序列可以与参比序列具有至少80％、85％、90％、95％、96％、97％、98％或99％的一致性(或同源性)。本发明所述的序列一致性可以使用序列分析软件测量。例如使用缺省参数的计算机程序BLAST，尤其是BLASTP或TBLASTN。本发明述及的氨基酸序列均按照N端至C端的方式示出。
如前所述，本发明的抗体可以是全长的(例如，IgG1或IgG4抗体)或可仅包含抗原结合部分(例如，Fab、F(ab’)2或scFv片段)，或可以被修饰以影响功能。本发明包括具有修饰的糖基化模式的抗B7H6抗体。在一些应用中，进行修饰以除去不期望的糖基化位点可以是有用的，或在寡糖链上不存在岩藻糖部分以例如增强抗体依赖性细胞毒性(ADCC)功能的抗体。在另一些应用中，可进行半乳糖基化修饰以改变补体依赖性细胞毒性(CDC)。
本文所使用的术语“功能性片段”尤其是指抗体片段如Fv、scFv(sc指单链)、Fab、F(ab’)2、Fab’、scFv-Fc片段或者双抗体(diabody)、或者通过化学修饰或通过掺入脂质体中应能够增加半寿期的任何片段，所述化学修饰例如添加聚(亚烷基)二醇，如聚乙二醇(“聚乙二醇化，PEG化”)(被称为Fv-PEG、scFv-PEG、Fab-PEG、F(ab’)2-PEG或Fab’-PEG的聚乙二醇化片段)(“PEG”为聚乙二醇)，所述片段具有B7H6结合活性。优选地，所述功能性片段将由其来源抗体的重链可变区或轻链可变区的部分序列构成或者包含它们，所述部分序列足以保留与其来源抗体相同的结合特异性和充分的亲和力，对于B7H6，优选至少等于其来源抗体亲和力的1/100，在更优选方式中至少等于1/10。这种功能片段将包含最少5个氨基酸，优选其来源的抗体序列的10、15、25、50和100个连续氨基酸。
如前所述，本发明提供了一种能够结合B7H6的抗体或其抗原结合片段，其特征在于，该抗体包括重链CDR1、重链CDR2和重链CDR3，以及轻链CDR1、轻链CDR2和轻链CDR3。
根据本发明，所述抗体能够结合B7H6，特别是SEQ ID NO:21所示的氨基酸序列。
本发明的优选实施方式中，为了进一步提高抗体的生物可接受性，还可以对抗体进行人源化，即，所述抗体为嵌合抗体或人源化抗体。术语“嵌合抗体”是指利用重组DNA技术，将来自一个物种(如小鼠)的单克隆抗体的恒定区氨基酸序列替换为来自另一个物种(如人)的抗体的恒定区而获得的重组抗体。术语“人源化抗体”是指利用重组DNA技术，将来自一个物种(如小鼠)的单克隆抗体的恒定区和可变区的非CDR(Fv骨架区(FR))氨基酸序列全部替换为来自另一个物种(如人)的抗体的恒定区和可变区的非CDR氨基酸序列而获得的重组抗体。也即，一个抗体的恒定区被人源化时称为嵌合抗体，而恒定区和可变区的非CDR氨基酸序列全部人源化后称为人源化抗体。人源化的方法可以参照常规的抗体工程技术进行，在此不再赘述。
本发明提供的人源化抗体的重链可变区的序列如SEQ ID NO:17所示，轻链可变区的序列如SEQ ID NO:18所示；或者，重链可变区的序列如SEQ ID NO:19所示，轻链可变区的序列如SEQ ID NO:20所示。
本发明提供的免疫缀合物含有治疗剂以及与治疗剂偶联的如前所述的抗体或其抗原结合片段。所述抗体或其抗原结合片段与治疗剂偶联的方式可以为常规的方式。
本发明提供的组合物含有如前所述的抗体或其抗原结合片段、和/或上述免疫缀合物、以及药学上可接受的载体。在某些实施方式中，所述组合物包括在时间和/或空间上分开的组合，只要其能够共同作用以实现本发明的目的。例如，所述组合物中所含的成分可以以整体施用于受试者，或者分开施用于受试者。当所述组合物中所含的成分分开地施用于受试者时，各个成分可以同时或依次施用于受试者。
术语“药学上可接受的”表明组合物能够给药至受试者而不产生妨碍组合物给药的不良生理反应。例如，“药学上可接受的载体”是指在制备一般安全、无毒、可取的药物组合物中有用的载体，优选地，这些载体或稀释剂的实例包括但不限于：水、盐水、林格氏溶液、葡萄糖、甘露醇、右旋葡萄糖、乳糖、淀粉、硬脂酸镁、纤维素、碳酸镁、0.3％甘油、透明质酸、乙醇、聚亚烷基二醇如聚丙二醇、甘油三酯、 5％人血清白蛋白，也可以使用脂质体和非水媒介物，例如不挥发油。
本发明的组合物也可以相互组合、或与一种或多种其它的治疗化合物组合地给药，例如，与化疗剂组合给药。因此，所述组合物还可以含有化疗剂。本发明的抗体或其抗
原结合片段、或免疫缀合物还可以与第二治疗剂组合，所述第二治疗剂的示例性试剂包括但不限于抑制B7H6活性的其他试剂(包括其他抗体或其抗原结合片段、肽抑制剂、小分子拮抗剂等)和/或干扰B7H6上游或下游信号转导的试剂。
通常，所述抗体或其抗原结合片段以有效量给药，即足以实现期望的治疗和/或预防效果的量，例如，引起与被治疗的疾病相关的症状的预防或缓解的量，所述疾病例如与B7H6相关的疾病。给药至受试者的组合物的有效量将取决于疾病的类型和严重度，以及取决于个体的特征，例如一般健康状态、年龄、性别、体重和对药物的耐受性；还将取决于疾病的严重程度和类型，本领域技术人员将能够根据这些因素等确定合适的剂量。
本发明提供的用于检测样品中B7H6的试剂盒含有如上所述的抗体或其抗原结合片段。所述样品可以为患有B7H6介导的疾病的患者(特别是移植排斥、自身免疫病、感染性疾病或癌症患者，更优选是患有肺癌，肝癌，卵巢癌，宫颈癌，皮肤癌，膀胱癌，结肠癌，乳腺癌，神经胶质瘤，肾癌，胃癌，食道癌，口腔鳞状细胞癌和头颈癌中的至少一种的患者)的组织。所述试剂盒还可以包括常规用于检测B7H6的试剂，如包被液等。
本发明还提供了如上所述的抗体或其抗原结合片段在制备用于检测样品中B7H6的试剂中的用途。如前所述，所述样品可以为患有B7H6介导的疾病的患者的组织，在此不再赘述。本发明的抗体或其抗原结合片段与B7H6具有良好的亲和性，能够有效地检测样品中的B7H6。
本发明还提供了所述的抗体或其抗原结合片段、免疫缀合物、组合物、核酸、重组载体或转化子或重组细胞在制备用于预防和/或治疗B7H6介导的疾病的药物中的用途。优选地，所述B7H6介导的疾病为移植排斥、自身免疫病、感染性疾病或癌症。更优选地，所述癌症为表达B7H6的癌症。进一步优选地，所述癌症为肺癌，肝癌，卵巢癌，宫颈癌，皮肤癌，膀胱癌，结肠癌，乳腺癌，神经胶质瘤，肾癌，胃癌，食道癌，口腔鳞状细胞癌和头颈癌中的至少一种。进一步优选地，所述感染性疾病包括但不限于HIV病毒感染和/或乙型肝炎病毒感染。
本发明涉及一种药物，所述药物包括前面所述的抗体或其抗原结合片段、免疫缀合物、组合物、核酸、重组载体或转化子或重组细胞。
根据本发明的一些具体实施例，上述药物可以包括下列附加技术特征中的至少之一：
根据本发明的一些具体实施例，所述药物包括药学上可接受的载体和有效量的所述抗体或其抗原结合片段、免疫缀合物、组合物、核酸、重组载体或转化子或重组细胞。
本发明还涉及一种预防和/或治疗B7H6介导的疾病(如前所述)的方法，该方法包括：将有效量的本发明的抗体或其抗原结合片段、免疫缀合物、组合物、重组细胞、核酸和药物中的至少一种给药至患者。其中，给药的方式可以为口服给药、经鼻给药、皮内给药、皮下给药、肌内给药或静脉给药或腹腔内给药。如前所述，所述抗体或其抗原结合片段能够有效与B7H6进行结合，进而促进B7H6与NKp30的相互作用，加强NK细胞抗癌功能。因此，所述抗体或其抗原结合片段，以及能够在合适的条件下表达获得所述抗体或其抗原结合片段的物质，或者包含所述抗体或其抗原结合片段的物质均能够有效预防和/或治疗B7H6介导的疾病，根据本发明实施例的方法能够有效预防和/或治疗B7H6介导的疾病。
根据本发明的一些具体实施例，上述方法还可以包括下列附加技术特征中的至少之一：
根据本发明的具体实施例，所述B7H6介导的疾病为癌症或感染性疾病。
根据本发明的具体实施例，所述癌症为肺癌，肝癌，卵巢癌，宫颈癌，皮肤癌，膀胱癌，结肠癌，乳腺癌，神经胶质瘤，肾癌，胃癌，食道癌，口腔鳞状细胞癌和头颈癌中的至少一种。
本发明中涉及的“患者”或“受试者”一般指哺乳动物，如灵长类动物和/或啮齿类动物，特别是人或鼠。
本领域技术人员可以将编码本发明所述抗体或其抗原结合片段的DNA分子克隆到载体(特别是表达载体)中，进而转化宿主细胞，通过诱导表达可获得所述抗体或其抗原结合片段。因此，本发明还提供了编码上述抗体或其抗原结合片段的(分离的)核酸以及含有该核酸的重组载体和转化子。所述核酸优选为基因工程手段获得的表达盒。
重组载体可以指克隆载体，也可以指表达载体，可以通过将所述核酸与商购的载体(如质粒或病毒载体)可操作地连接而获得，常用的质粒包括pSeTag2、PEE14、pMH3等。
本发明的表达载体可以含有编码的所述抗体的重链可变区、轻链可变区和/或恒定区的DNA序列。然而，也可以分别构建两种表达载体，一种含有重链可变区和恒定区，另一种含有轻链可变区和恒定区，一同转染哺乳动物细胞。在一个优选的实施方式中，所述表达载体进一步含有启动子和编码分泌信号肽的DNA序列，以及至少一种用于筛选的抗药基因。
本发明所述宿主细胞可以为原核宿主细胞、真核宿主细胞或噬菌体。所述原核宿主细胞可以为大肠杆菌、枯草杆菌、链霉菌或奇异变形菌等。所述真核宿主细胞可以为包括巴斯德毕赤酵母、酿酒酵母、裂殖酵母、木霉等真菌，草地粘虫等昆虫细胞，烟草等植物细胞，BHK细胞、CHO细胞、COS细胞、骨髓瘤细胞等哺乳动物细胞。在一些实施方式中，本发明所述宿主细胞优选为哺乳动物细胞，更优选BHK细胞、CHO细胞、NSO细胞或COS细胞。
本发明涉及一种重组细胞，所述重组细胞携带前面所述的核酸、重组载体或转化子、或抗体或抗原结合片段。所述重组细胞是通过转染或者转化所述表达载体获得的。根据本发明的实施例，所述重组细胞在合适条件下可高效表达上述抗体，所述抗体或其抗原结合片段能够有效与B7H6进行结合，进一步地，所述抗体或抗原结合片段具有良好的预防和/或治疗B7H6介导的疾病的效果。
需要注意的是，本发明所述重组细胞不受特别限制，可以为原核细胞、真核细胞或噬菌体。所述原核细胞可以为大肠杆菌、枯草杆菌、链霉菌或奇异变形菌等。所述真核细胞可以为包括巴斯德毕赤酵母、酿酒酵母、裂殖酵母、木霉等真菌，草地粘虫等昆虫细胞，烟草等植物细胞，BHK细胞、CHO细胞、COS细胞、骨髓瘤细胞等哺乳动物细胞。在一些实施例中，本发明所述重组细胞优选为哺乳动物细胞，包括BHK细胞、CHO细胞、NSO细胞或COS细胞，且不包括动物生殖细胞、受精卵或胚胎干细胞。
需要说明的是，本申请说明书中所述的“适合条件”，是指适合本申请所述抗体或其抗原结合片段表达的条件。本领域技术人员容易理解的是，适合抗体或抗原结合片段表达的条件包括但不限于合适的转化或转染方式、合适的转化或转条件、健康的宿主细胞状态、合适的宿主细胞密度、适宜的细胞培养环境、适宜的细胞培养时间。“适合条件”不受特别限制，本领域技术人员可根据实验室的具体环境，优化最适的所述抗体或其抗原结合片段表达的条件。
本发明还涉及前面所述的抗体或其抗原结合片段、免疫缀合物、组合物、药物、核酸、重组载体或转化子或重组细胞在治疗和/或预防B7H6介导的疾病中的用途。如前所述，所述抗体或其抗原结合片段能够有效与B7H6进行结合，进而促进B7H6与NKp30的相互作用，加强NK细胞抗癌功能，因此，所述抗体或其抗原结合片段，以及能够在合适的条件下表达获得所述抗体或其抗原结合片段的物质均能够有效预防和/或治疗B7H6介导的疾病。
根据本发明的具体实施例，上述治疗和/或预防B7H6介导的疾病中的用途还可以包括下列附加技术特征中的至少之一：
根据本发明的具体实施例，所述B7H6介导的疾病为癌症或感染性疾病。
根据本发明的具体实施例，所述癌症为肺癌，肝癌，卵巢癌，宫颈癌，皮肤癌，膀胱癌，结肠癌，乳腺癌，神经胶质瘤，肾癌，胃癌，食道癌，口腔鳞状细胞癌和头颈癌中的至少一种。
在本发明的又一方面，本发明提出了一种诊断受试者是否患有B7H6介导的疾病的方法。根据本发明的具体实施例，所述方法包括使用下列中的至少之一对待测样品中的B7H6进行检测：1)前面所述的抗体或其抗原结合片段；2)前面所述的核酸；3)前面所述的重组载体或转化子；和4)前面所述的重组细胞，基于所述B7H6的检测结果，确定所述待测样品中B7H6的含量。如前所述，本发明实施例的抗体或抗原结合片段能够有效与B7H6进行结合，因此，所述抗体或抗原结合片段可用于检测B7H6，而B7H6介导多种疾病，因此，根据受试者来源的生物样品中含有的所述B7H6的水平可以判断所述受试者是否患有B7H6介导的疾病。此外，还可以利用上述物质监控受试者待测样品中的B7H6的含量，即上述物质也可以用于对患有B7H6介导的疾病的受试者进行疾病分期，也可以用于B7H6介导的疾病的预后评估。
根据本发明的具体实施例，上述方法还可以进一步包括下列附加技术特征中的至少之一：
根据本发明的具体实施例，所述待测样品中B7H6的含量不低于患病的最低标准是待测样品来源于 患有B7H6介导的疾病的患者的指示。所述最低标准的值可以通过对大量患有所述B7H6介导的疾病的个体和大量健康个体的待测样本中的B7H6的含量进行差异比较分析、以及验证，而确定下来。
根据本发明的具体实施例，所述B7H6介导的疾病为癌症或感染性疾病。
根据本发明的具体实施例，所述癌症为肺癌，肝癌，卵巢癌，宫颈癌，皮肤癌，膀胱癌，结肠癌，乳腺癌，神经胶质瘤，肾癌，胃癌，食道癌，口腔鳞状细胞癌和头颈癌中的至少一种。
根据本发明的具体实施例，所述待测样品包括下列中的至少之一：组织、细胞、血液、血清、汗液、粪便和尿液。
在本发明的另一方面，本发明提出了下列中的至少之一在诊断受试者是否患有B7H6介导的疾病中的用途：1)前面述的抗体或其抗原结合片段；2)前面所述的核酸；3)前面所述的重组载体或转化子；和4)前面所述的重组细胞。如前所述，本发明实施例的抗体或抗原结合片段能够有效与B7H6进行结合，因此，所述抗体或抗原结合片段可用于检测B7H6，而B7H6介导多种疾病，因此，根据受试者来源的生物样品中含有的所述B7H6的水平可以判断所述受试者是否患有B7H6介导的疾病。
根据本发明的具体实施例，上述用途还可以进一步包括下列附加技术特征中的至少之一：
根据本发明的具体实施例，所述B7H6介导的疾病为癌症或感染性疾病。
根据本发明的具体实施例，所述癌症为肺癌，肝癌，卵巢癌，宫颈癌，皮肤癌，膀胱癌，结肠癌，乳腺癌，神经胶质瘤，肾癌，胃癌，食道癌，口腔鳞状细胞癌和头颈癌中的至少一种。
本发明所涉及的序列说明详见表1。
表1氨基酸序列说明表
Figure PCTCN2022137095-appb-000001
Figure PCTCN2022137095-appb-000002
Figure PCTCN2022137095-appb-000003
Figure PCTCN2022137095-appb-000004
编码本发明的抗体的重链和/或轻链的核酸在本发明的范围内，根据重链和/或轻链的氨基酸序列，本领域技术人员能够很容易得到相应的核酸序列，如表2所示。
表2核苷酸序列说明表
Figure PCTCN2022137095-appb-000005
Figure PCTCN2022137095-appb-000006
Figure PCTCN2022137095-appb-000007
Figure PCTCN2022137095-appb-000008
Figure PCTCN2022137095-appb-000009
Figure PCTCN2022137095-appb-000010
Figure PCTCN2022137095-appb-000011
Figure PCTCN2022137095-appb-000012
Figure PCTCN2022137095-appb-000013
以下将通过实施例对本发明进行详细描述。实施例或测试例中，未注明具体条件的实验方法的，均按照常规条件进行。
下面将结合实施例对本发明的方案进行解释。本领域技术人员将会理解，下面的实施例仅用于说明本发明，而不应视为限定本发明的范围。实施例中未注明具体技术或条件的，按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者，均为可以通过市购获得的常规产品。
实施例1抗体的制备
生成针对人B7H6的鼠源单克隆抗体，用纯化的重组B7H6胞外区Fc融合蛋白(B7H6-Fc)(重组B7H6胞外区Fc融合蛋白，氨基酸序列如SEQ ID NO:22所示)作为抗原，免疫Balb/c小鼠(9周龄，购自上海莱斯克，体重20g左右)。
免疫小鼠使用纯化抗原和完全弗氏佐剂进行3次免疫，通过尾静脉放血后检测免疫应答。通过ELISA、流式细胞术筛选血清，获取有抗人B7H6免疫球蛋白的小鼠。并对有最高的抗B7H6免疫球蛋白的小鼠取出脾细胞与鼠骨髓瘤细胞SP2/0细胞(ATCC编号CRL-1581)进行融合。融合后的杂交瘤细胞进行抗体筛选，得到鼠单抗。
将候选杂交瘤细胞总数量培养到106，800rpm离心10分钟收集细胞，并以Trizol试剂盒(Invitrogen)提取总RNA；以总RNA为模板，逆转录合成cDNA文库(Invitrogen)，又以cDNA为模板PCR扩增杂交瘤细胞的所对应的可变区核酸序列。PCR扩增反应中所使用的引物序列与抗体可变区第一框架区或信号肽区和恒定区互补(Larrick，J.W.，et al.，(1990)Scand.J.Immunol.，32，121-128和Coloma，J.J.et al.，(1991)BioTechniques，11，152-156)。在50μl反应体系中，分别加入cDNA2μL，10×PCR缓冲液5μL，上游及下游引物2μL(5μmol)，dNTP 2μL，Taq酶1μLL(Takara，Ex Taq)，H2O 38μL；95℃预变性5min，进入温度循环，进行PCR扩增。反应条件为：94℃变性30S，58℃退火45S，72℃延伸50S，共32个循环，然后72℃延长7min。将扩增产物测序后，得到鼠单抗的重链和轻链可变区序列(包括氨基酸序列和核酸序列)。
实施例2：鼠源B7H6抗体ELISA结合实验
ELISA实验被用于检测B7H6抗体的结合特性。B7H6胞外区Fc融合蛋白(B7H6-Fc)包被到96孔板中，抗体加入后信号的强弱用于判断抗体和B7H6的结合特性。
用PBS缓冲液将B7H6-Fc融合蛋白(氨基酸序列如SEQ ID NO:22所示)稀释为1μg/mL，以100μL/孔的体积加于96孔板中，于4℃放置过夜。将96孔板中PBS缓冲液吸掉，用PBST(pH7.2PBS含0.1％Tween 20)缓冲液洗板6次后，加入200μL/孔PBS/10％BSA，37℃孵育2h进行封闭。移去封闭液，用PBST洗板6次后，加入100μL/孔用PBST/0.05％BSA稀释至合适浓度的待测B7H6抗体，37℃孵育1h。移去反应体系，用PBST洗板6次后，以100μL/孔用PBST/0.05％BSA稀释HRP(辣根过氧化物酶)标记的抗鼠抗体二抗，37℃孵育1h。用PBST洗板6次后，加入80μL/孔TMB(四甲基联苯胺)，于室温孵育3min，加入80μL/孔4M硫酸终止反应。用酶标仪在450mm处读取吸光值。结果(图1)表明本发明的鼠源抗体12F5(SEQ ID NO:26和SEQ ID NO:27)、12G4(SEQ ID NO:28和SEQ ID NO:29)能够结合B7H6。
实施例3：鼠源B7H6抗体流式细胞术结合实验
流式细胞术实验被用于检测B7H6抗体的结合特性，于HL60细胞(ATCC编号CCL-240)中过表达B7H6蛋白(HL60-B7H6、SEQ ID NO:21；SEQ ID NO:54)，表达载体为pLVX-EF1a-B7H6-IRES-ZsGreen，抗体加入后信号的强弱用于判断抗体和B7H6的结合特性。
HEK293T细胞按照5×105细胞/孔铺六孔板，用不含双抗的DMEM培养基培养过夜。转染前弃去培养基，加入1mL新鲜的不含双抗的DMEM培养基。将pLVX-EF1a-B7H6-IRES-ZsGreen(pLVX-EF1a-IRES-ZsGreen1载体的酶切位点EcoRI与BamHI之间插入有B7H6蛋白(SEQ ID NO:21)的编码序列(SEQ ID NO:54)、pMD2G、psPAX2载体(共3μg)按照2:1:1的比例加入200μl无血清DMEM培养基中，加入12μg聚醚酰亚胺(PEI，Polysciences有限公司)。混匀后静置16min，然后将全部液体加入铺有HEK293T细胞的六孔板中。培养6h后，弃去培养基，加入新鲜的完全DMEM培养基培养。转染48h后，收细胞培养上清，过0.45μm滤器(Millipore)，即为病毒上清。将病毒上清全部加入含有1×104HL60细胞的6孔板中，加入终浓度4μg/ml的聚凝胺(Sigma)，培养12h。随后弃尽上清，加入新鲜的完全RPMI1640培养基。所得细胞即为HL60-B7H6细胞。
用PBS将HL60-B7H6细胞稀释为2×106/mL，以100μL/管的体积加于1.5ml EP管中，向其中加入10μL/管山羊血清，于4℃封闭30min。加入1μg/管的B7H6抗体，于4℃孵育30min。向EP管中加入1mL PBS，4℃3500rpm×5min离心，弃尽上清，再用PBS洗一遍。离心后弃尽上清，用100μl/管PBS重悬细胞，向其中加入0.1μL/管Alexa-647标记的山羊抗小鼠抗体二抗(Invitrogen)，4℃避光孵育30min。用PBS洗两遍，离心后弃尽上清。用200μL/管PBS重悬细胞，用流式细胞仪进行检测，结果如图2所示，进一步显示本发明的鼠源抗体12F5(SEQ ID NO:26和SEQ ID NO:27)、12G4(SEQ ID NO:28和SEQ ID NO:29)能够结合B7H6。
实施例4：小鼠抗体人源化实验
参照B7H6抗体轻链可变区序列和重链可变区序列，选取与其非CDR区匹配最好的人源化模板。将鼠源抗体CDR区移植到选择的人源化模板上，替换人源模板的CDR区，得到人源化的抗体。然后，以鼠源抗体的三维结构为基础，对包埋残基、与CDR区有直接相互作用的残基，以及对VL和VH的构象有重要影响的残基进行回复突变，得到人源化之后的抗体，人源化B7H6抗体12F5重链可变区的 序列如SEQ ID NO:17所示，轻链可变区序列如SEQ ID NO:18所示，或者，人源化B7H6抗体12G4重链可变区的序列如SEQ ID NO:19所示，轻链可变区序列如SEQ ID NO:20所示。
实施例5：人源化B7H6抗体ELISA结合实验
ELISA实验被用于检测人源化B7H6抗体的结合特性。B7H6胞外区Fc融合蛋白(B7H6-Fc)包被到96孔板中，抗体加入后信号的强弱用于判断抗体和B7H6的结合特性。
用PBS缓冲液将B7H6-Fc融合蛋白(氨基酸序列如SEQ ID NO:22所示)稀释为1μg/mL，以100μL/孔的体积加于96孔板中，于4℃放置过夜。将96孔板中PBS缓冲液吸掉，用PBST(pH7.2PBS含0.1％Tween 20)缓冲液洗板6次后，加入200μL/孔PBS/10％BSA，37℃孵育2h进行封闭。移去封闭液，用PBST洗板6次后，加入100μL/孔用PBST/0.05％BSA稀释至合适浓度的待测B7H6抗体，37℃孵育1h。移去反应体系，用PBST洗板6次后，以100μL/孔用PBST/0.05％BSA稀释HRP(辣根过氧化物酶)标记的小鼠抗人IgG(Fab特异性)二抗(Sigma)，37℃孵育1h。用PBST洗板6次后，加入80μL/孔TMB(四甲基联苯胺)，于室温孵育3min，加入80μL孔4M硫酸终止反应。用酶标仪在450mm处读取吸光值。结果(图3)表明本发明的人源化抗体h12F5(SEQ ID NO:30和SEQ ID NO:31)、h12G4(SEQ ID NO:32和SEQ ID NO:33)能够结合B7H6。
实施例6：人源化B7H6抗体流式细胞术结合实验
流式细胞术实验被用于检测B7H6抗体的结合特性，于HL60细胞(ATCC编号CCL-240)中过表达B7H6蛋白(HL60-B7H6)(如实施例3中所示)，抗体加入后信号的强弱用于判断抗体和B7H6的结合特性。
用PBS将HL60-B7H6细胞稀释为2×106/mL，以100μL/管的体积加于1.5mL EP管中，向其中加入10μL/管小鼠血清，于4℃封闭30min。加入1μg/管的B7H6抗体，于4℃孵育30min。向EP管中加入1mL PBS，4℃3500rpm×5min离心，弃尽上清，再用PBS洗一遍。离心后弃尽上清，用100μL/管PBS重悬细胞，向其中加入1μL/管Alexa-647标记的小鼠抗人IgG-Fc二抗(Biolegend)，4℃避光孵育30min。用PBS洗两遍，离心后弃尽上清。用200μL/管PBS重悬细胞，用流式细胞仪进行检测，结果如图4所示，进一步显示本发明的人源化抗体h12F5(SEQ ID NO:30和SEQ ID NO:31)、h12G4(SEQ ID NO:32和SEQ ID NO:33)能够结合B7H6。
实施例7：人源化B7H6抗体流式细胞术结合实验
流式细胞术实验被用于检测人源化B7H6抗体的结合特性，于CHO-K1细胞(ATCC编号CCL-240)中过表达猴B7H6蛋白(CHO-K1-cyno-B7H6)，抗体加入后信号的强弱用于判断抗体和猴B7H6的结合特性。
HEK293T细胞按照5×105细胞/孔铺六孔板，用不含双抗的DMEM培养基培养过夜。转染前弃去培养基，加入1mL新鲜的不含双抗的DMEM培养基。将pLVX-EF1a-cynoB7H6-IRES-ZsGreen(pLVX-EF1a-IRES-ZsGreen1载体的酶切位点EcoRI与BamHI之间插入有猴B7H6蛋白(SEQ ID NO:24)的编码序列(SEQ ID NO:57)、pMD2G、psPAX2载体(共3μg)按照2:1:1的比例加入200μL无血清DMEM培养基中，加入12μg聚醚酰亚胺(PEI，Polysciences有限公司)。混匀后静置16min，然后将全部液体加入铺有HEK293T细胞的六孔板中。培养6h后，弃去培养基，加入新鲜的完全DMEM培养基培养。转染48h后，收细胞培养上清，过0.45μm滤器(Millipore)，即为病毒上清。将病毒上清全部加入含有1×104 CHO-K1细胞的6孔板中，加入终浓度4μg/ml的聚凝胺(Sigma)，培养12h。随后弃尽上清，加入新鲜的完全RPMI1640培养基。所得细胞即为CHO-K1-cyno B7H6细胞。
用PBS将CHO-K1-cynoB7H6细胞稀释为2×106/mL，以100μL/管的体积加于1.5mLEP管中，向其中加入10μL/管小鼠血清，于4℃封闭30min。加入1μg/管的人源化B7H6抗体，于4℃孵育30min。向EP管中加入1mL PBS，4℃3500rpm×5min离心，弃尽上清，再用PBS洗一遍。离心后弃尽上清，用100μL/管PBS重悬细胞，向其中加入1μL/管Alexa-647标记的小鼠抗人IgG-Fc二抗(Biolegend)，4℃避光孵育30min。用PBS洗两遍，离心后弃尽上清。用200μL/管PBS重悬细胞，用流式细胞仪进行检测，结果如图5所示，进一步显示本发明的抗体h12F5、h12G4能够结合猴B7H6。
实施例8：人源化B7H6抗体ELISA结合实验
ELISA实验被用于检测人源化B7H6抗体的结合特性。猴B7H6胞外区Fc融合蛋白(cynoB7H6-Fc) 包被到96孔板中，抗体加入后信号的强弱用于判断抗体和猴B7H6的结合特性。
用PBS缓冲液将cynoB7H6-Fc融合蛋白(氨基酸序列如SEQ ID NO:23所示)稀释为1μg/mL，以100μL/孔的体积加于96孔板中，于4℃放置过夜。将96孔板中PBS缓冲液吸掉，用PBST(pH7.2 PBS含0.1％Tween 20)缓冲液洗板6次后，加入200μL/孔PBS/10％BSA，37℃孵育2h进行封闭。移去封闭液，用PBST洗板6次后，加入100μL/孔用PBST/0.05％BSA稀释至合适浓度的待测B7H6抗体，37℃孵育1h。移去反应体系，用PBST洗板6次后，以100μL/孔用PBST/0.05％BSA稀释HRP(辣根过氧化物酶)标记的小鼠抗人IgG(Fab特异性)二抗(Sigma)，37℃孵育1h。用PBST洗板6次后，加入80μL/孔TMB(四甲基联苯胺)，于室温孵育3min，加入80μL/孔4M硫酸终止反应。用酶标仪在450mm处读取吸光值。结果(图6)表明本发明的人源化抗体h12G4能够结合猴B7H6。
实施例9：体外结合亲和力和动力学实验
Biacore方法是公认的客观检测蛋白相互间亲和力和动力学的检测方法，通过Biacore T200分析本发明B7H6抗体表征亲和力及结合动力学。
采用标准氨基偶联法将B7H6胞外段Fc融合蛋白(B7H6-Fc)共价连接至CM5(GE)芯片上。然后将稀释于PBS中的一系列浓度梯度的B7H6抗体与各个循环进样，进样后以10mM NaOH溶液再生。追踪抗原-抗体结合动力学3分钟并追踪解离动力学10分钟，使用GE的BIAevaluation软件以1:1(Langmuir)结合模型分析所得数据。以此法测定的鼠源12F5的KD值为2.2nM，鼠源12G4的KD值为0.15nM。
实施例10：抗体促进B7H6结合NKp30能力的筛选
B7H6抗体是通过和B7H6胞外区的结合，从而促进B7H6和其受体NKp30的信号通路，流式细胞术实验被用于检测B7H6抗体对受体NKp30结合的增强。
用PBS将HL60-B7H6细胞(同上)稀释为2×106/ml，以100μL/管的体积加于1.5mL EP管中，向其中加入10μL/管小鼠血清，于4℃封闭30min。加入4μg/管NKp30胞外区Fc融合蛋白(NKp30-Fc，SEQ ID NO:25，本实验室表达)，4℃孵育30min。加入B7H6抗体，于4℃孵育30min。向EP管中加入1mL PBS，4℃3500rpm×5min离心，弃尽上清，再用PBS洗一遍。离心后弃尽上清，用100μl/管PBS重悬细胞，向其中加入1μL/管647标记的小鼠抗人抗体二抗(Biolegend)，4℃避光孵育30min。用PBS洗两遍，离心后弃尽上清。用200μL/管PBS重悬细胞，用流式细胞仪进行检测，结果如图7所示，可以看出，本发明的鼠源12F5抗体够促进B7H6与受体NKp30的结合。
实施例11：补体依赖的细胞毒检测
补体依赖的细胞毒实验，用于检测B7H6抗体杀伤肿瘤细胞的作用。其中，使用的肿瘤细胞为HL60-B7H6细胞。
(1)肿瘤细胞用无血清RPMI-1640培养基重悬，计数。用完全RPMI-1640培养基稀释为4×105/mL。以25μL/孔的体积将稀释后的细胞加入96孔圆底板中
(2)用无血清RPMI-1640培养基稀释B7H6抗体或对照鼠IgG，以25μL/孔的体积将稀释后的B7H6抗体或鼠IgG加入96孔圆底板中。
(3)用1mL超纯水溶解兔补体(Cedarlane)，然后加入1mL无血清RPMI-1640培养基，混匀后作为工作液。以40μL/孔的体积将补体工作液加入96孔圆底板中。37℃孵育30min。
(4)以110μL/孔的体积将完全RPMI-1640培养基加入96孔圆底板中，以1μL/孔的体积向96孔圆底板中加入7-AAD(BD)，混匀。将孔中所有液体转入流式管，利用流式细胞仪进行检测。结果如图8所示，可以看出，本发明B7H6鼠源12F5抗体有补体依赖细胞毒作用。
实施例12：B7H6抗体促进小鼠抗癌能力
体内药效实验，用于检测B7H6抗体促进裸鼠抗癌功能。其中，使用的肿瘤细胞分别为急性髓系白血病U-937细胞(ATCC编号CRL-1953.2)。
(1)裸鼠右腹侧皮下荷瘤，每只鼠1.5×106 U-937细胞，然后将小鼠随机分组。
(2)第5、7、9、11、13天，为小鼠腹腔注射抗体，每只鼠1mg。
(3)每2天测量一次肿瘤体积。
结果如图9所示，可以看出，本发明的鼠源抗体12F5具有抗癌功能。
从以上实验结果可以看出，本发明得到的抗体的能够结合人与猴B7H6；能够促进B7H6和NKp30的相互作用；能够促进小鼠抗癌。
以上详细描述了本发明的优选实施方式，但是，本发明并不限于此。在本发明的技术构思范围内，可以对本发明的技术方案进行多种简单变型，包括各个技术特征以任何其它的合适方式进行组合，这些简单变型和组合同样应当视为本发明所公开的内容，均属于本发明的保护范围。
在本说明书的描述中，参考术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中，对上述术语的示意性表述不必须针对的是相同的实施例或示例。而且，描述的具体特征、结构、材料或者特点可以在任一个或多个实施例或示例中以合适的方式结合。此外，在不相互矛盾的情况下，本领域的技术人员可以将本说明书中描述的不同实施例或示例以及不同实施例或示例的特征进行结合和组合。
尽管上面已经示出和描述了本发明的实施例，可以理解的是，上述实施例是示例性的，不能理解为对本发明的限制，本领域的普通技术人员在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。

Claims (27)

  1. 一种能够结合B7H6的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包括重链CDR1、重链CDR2和重链CDR3，以及轻链CDR1、轻链CDR2和轻链CDR3，其中，
    所述重链CDR1包含选自SEQ ID NO:1、SEQ ID NO:7所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一；
    所述重链CDR2包含选自SEQ ID NO:2、SEQ ID NO:8所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一；
    所述重链CDR3包含选自EQ ID NO:3、SEQ ID NO:9所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一；
    所述轻链CDR1包含选自EQ ID NO:4、SEQ ID NO:10所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一；
    所述轻链CDR2包含自SEQ ID NO:5、SEQ ID NO:11所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一；以及
    所述轻链CDR3含选自SEQ ID NO:6、SEQ ID NO:12所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一。
  2. 根据权利要求1所述的抗体或其抗原结合片段，其中，所述的抗体或其抗原结合片段包含：
    1)具有SEQ ID NO:1所示的氨基酸序列的重链CDR1，具有SEQ ID NO:2所示的氨基酸序列的重链CDR2，具有SEQ ID NO:3所示的氨基酸序列的重链CDR3，具有SEQ ID NO:4所示的氨基酸序列的轻链CDR1，具有SEQ ID NO:5所示的氨基酸序列的轻链CDR2，具有SEQ ID NO:6所示的氨基酸序列的轻链CDR3：或
    2)具有SEQ ID NO:7所示的氨基酸序列的重链CDR1，具有SEQ ID NO:8所示的氨基酸序列的重链CDR2，具有SEQ ID NO:9所示的氨基酸序列的重链CDR3，具有SEQ ID NO:10所示的氨基酸序列的轻链CDR1，具有SEQ ID NO:11所示的氨基酸序列的轻链CDR2，具有SEQ ID NO:12所示的氨基酸序列的轻链CDR3。
  3. 根据权利要求1或2所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包括重链可变区和轻链可变区，(i)所述重链可变区包含SEQ ID NO:13、SEQ ID NO:15、SEQ ID NO:17、SEQ ID NO:19所示的氨基酸序列及其保守修饰形式的氨基酸序列至少之一至少80％同源性的氨基酸序列；和/或，(ii)所述轻链可变区包含SEQ ID NO:14、SEQ ID NO:16、SEQ ID NO:18、SEQ ID NO:20所示的氨基酸序列及其保修修饰形式的氨基酸序列至少之一至少80％同源性的氨基酸序列。
  4. 根据权利要求1-3任一项所述的抗体或其抗原结合片段，其中，所述重链可变区包含与选自(i)中的重链可变区至少90％，至少95％，至少96％，至少97％，至少98％，至少99％或者100％同源性的氨基酸序列；所述轻链可变区包含与选自(ii)中的轻链可变区至少90％，至少95％，至少96％，至少97％，至少98％，至少99％或者100％同源性的氨基酸序列。
  5. 根据权利要求1-4任一项所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包括：
    1)所述重链可变区如SEQ ID NO:13所示的氨基酸序列，以及所述轻链可变区如SEQ ID NO:14所示的氨基酸序列；
    2)所述重链可变区如SEQ ID NO:15所示的氨基酸序列，以及所述轻链可变区如SEQ ID NO:16所示的氨基酸序列；
    3)所述重链可变区如SEQ ID NO:17所示的氨基酸序列，以及所述轻链可变区如SEQ ID NO:18所示的氨基酸序列；或
    4)所述重链可变区如SEQ ID NO:19所示的氨基酸序列，以及所述轻链可变区如SEQ ID NO:20所示的氨基酸序列。
  6. 根据权利要求1-5任一项所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段包括：
    1)所述重链如SEQ ID NO:26所示的氨基酸序列，以及所述轻链如SEQ ID NO:27所示的氨基酸序列；
    2)所述重链如SEQ ID NO:28所示的氨基酸序列，以及所述轻链如SEQ ID NO:29所示的氨基酸序列；
    3)所述重链如SEQ ID NO:30所示的氨基酸序列，以及所述轻链如SEQ ID NO:31所示的氨基酸序列；或
    4)所述重链如SEQ ID NO:32所示的氨基酸序列，以及所述轻链如SEQ ID NO:33所示的氨基酸序 列。
  7. 根据权利要求1-5任一项所述的抗体或其抗原结合片段，其中，所述的分离的抗体是IgG1、IgG2或IgG4。
  8. 根据权利要求1-5中任一项所述的抗体或其抗原结合片段，其中，所述抗体为单克隆抗体、鼠源抗体、嵌合抗体、人源化抗体人改造抗体、人抗体、Fv、单链抗体(scFv)、Fab、Fab’，Fab’-SH或者F(ab’)2。
  9. 根据权利要求1-8任一项所述的抗体或其抗原结合片段，其中，所述抗体或其抗原结合片段能够结合SEQ ID NO:21所示的氨基酸序列。
  10. 一种免疫缀合物，其中，该免疫缀合物含有治疗剂以及与治疗剂偶联的权利要求1-9中任一项所述的抗体或其抗原结合片段。
  11. 一种组合物，其中，所述组合物含有权利要求1-9中任一项所述的抗体或其抗原结合片段、和/或权利要求10所述的免疫缀合物、以及药学上可接受的载体。
  12. 一种用于检测样品中B7H6的试剂盒，该试剂盒含有权利要求1-9中任一项所述抗体或其抗原结合片段。
  13. 权利要求1-9中任一项所述的抗体或其抗原结合片段在制备用于检测样品中B7H6的试剂中的用途。
  14. 权利要求1-9中任一项所述的抗体或其抗原结合片段在制备用于预防和/或治疗B7H6介导的疾病的药物中的用途，所述B7H6介导的疾病为癌症或感染性疾病；
    任选地，所述癌症为肺癌，肝癌，卵巢癌，宫颈癌，皮肤癌，膀胱癌，结肠癌，乳腺癌，神经胶质瘤，肾癌，胃癌，食道癌，口腔鳞状细胞癌和头颈癌中的至少一种。
  15. 一种核酸，其包含编码权利要求1-9中任一项所述的抗体或其抗原结合片段的核酸。
  16. 一种重组载体或转化子，其含有权利要求15中所述的核酸。
  17. 一种重组细胞，其中，所述重组细胞携带权利要求15所述的核酸、权利要求16所述的表达载体或转化子、或权利要求1-9任一项所述的抗体或其抗原结合片段。
  18. 一种药物，其中，包括权利要求1-9任一项所述的抗体或其抗原结合片段、权利要求10所述的免疫缀合物、权利要求11所述的组合物、权利要求15所述的核酸、权利要求16所述的重组载体或转化子或权利要求17所述的重组细胞。
  19. 权利要求1-9任一项所述的抗体或其抗原结合片段、权利要求10所述的免疫缀合物、权利要求11所述的组合物、权利要求18所述的药物、权利要求15所述的核酸、权利要求16所述的重组载体或转化子或权利要求17所述的重组细胞在治疗和/或预防B7H6介导的疾病中的用途。
  20. 根据权利要求19所述的用途，其中，所述B7H6介导的疾病为癌症或感染性疾病；
    任选地，所述癌症为肺癌，肝癌，卵巢癌，宫颈癌，皮肤癌，膀胱癌，结肠癌，乳腺癌，神经胶质瘤，肾癌，胃癌，食道癌，口腔鳞状细胞癌和头颈癌中的至少一种。
  21. 一种治疗和/或预防B7H6介导的疾病的方法，其中，包括向受试者施用以下中的至少之一：
    1)权利要求1-9任一项所述的抗体或其抗原结合片段；
    2)权利要求10所述的免疫缀合物；
    3)权利要求11所述的组合物；
    4)权利要求18所述的药物；
    5)权利要求15所述的核酸；
    6)权利要求16所述的重组载体或转化子；和
    7)权利要求17所述的重组细胞。
  22. 根据权利要求21所述的方法，其特征在于，所述B7H6介导的疾病为癌症或感染性疾病；
    任选地，所述癌症为肺癌，肝癌，卵巢癌，宫颈癌，皮肤癌，膀胱癌，结肠癌，乳腺癌，神经胶质瘤，肾癌，胃癌，食道癌，口腔鳞状细胞癌和头颈癌中的至少一种。
  23. 一种诊断受试者是否患有B7H6介导的疾病的方法，其特征在于，包括使用下列中的至少之一对待测样品中的B7H6进行检测：
    1)权利要求1-9任一项所述的抗体或其抗原结合片段；
    2)权利要求15所述的核酸；
    3)权利要求16所述的重组载体或转化子；和
    4)权利要求17所述的重组细胞，
    基于所述B7H6的检测结果，确定所述待测样品中B7H6的含量。
  24. 根据权利要求23所述的方法，其特征在于，所述待测样品中B7H6的含量不低于患病的最低标准是待测样品来源于患有B7H6介导的疾病的患者的指示。
  25. 根据权利要求23所述的方法，其特征在于，所述B7H6介导的疾病为癌症或感染性疾病；
    任选地，所述癌症为肺癌，肝癌，卵巢癌，宫颈癌，皮肤癌，膀胱癌，结肠癌，乳腺癌，神经胶质瘤，肾癌，胃癌，食道癌，口腔鳞状细胞癌和头颈癌中的至少一种。
  26. 下列中的至少之一在诊断受试者是否患有B7H6介导的疾病中的用途：
    1)权利要求1-9任一项所述的抗体或其抗原结合片段；
    2)权利要求15所述的核酸；
    3)权利要求16所述的重组载体或转化子；和
    4)权利要求17所述的重组细胞。
  27. 根据权利要求26所述的用途，其中，所述B7H6介导的疾病为癌症或感染性疾病；
    任选地，所述癌症为肺癌，肝癌，卵巢癌，宫颈癌，皮肤癌，膀胱癌，结肠癌，乳腺癌，神经胶质瘤，肾癌，胃癌，食道癌，口腔鳞状细胞癌和头颈癌中的至少一种。
PCT/CN2022/137095 2021-12-07 2022-12-07 B7h6抗体及其应用 WO2023104062A1 (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2022404479A AU2022404479A1 (en) 2021-12-07 2022-12-07 B7h6 antibody and use thereof
IL310514A IL310514A (en) 2021-12-07 2022-12-07 Antibody B7H6 and its uses
EP22903484.8A EP4378956A1 (en) 2021-12-07 2022-12-07 B7h6 antibody and use thereof
MX2024003129A MX2024003129A (es) 2021-12-07 2022-12-07 Anticuerpo b7h6 y uso del mismo.
CA3227094A CA3227094A1 (en) 2021-12-07 2022-12-07 B7h6 antibody and use thereof
KR1020247004588A KR20240032996A (ko) 2021-12-07 2022-12-07 B7h6 항체 및 이의 응용
JP2024506277A JP2024529526A (ja) 2021-12-07 2022-12-07 Ｂ７ｈ６抗体及びその使用
ZA2024/00968A ZA202400968B (en) 2021-12-07 2024-01-29 B7h6 antibody and use thereof
US18/584,875 US20240190968A1 (en) 2021-12-07 2024-02-22 B7h6 antibody and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111485380.9A CN114395045B (zh) 2021-12-07 2021-12-07 B7h6抗体及其应用
CN202111485380.9 2021-12-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/584,875 Continuation US20240190968A1 (en) 2021-12-07 2024-02-22 B7h6 antibody and use thereof

Publications (1)

Publication Number Publication Date
WO2023104062A1 true WO2023104062A1 (zh) 2023-06-15

Family

ID=81225502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/137095 WO2023104062A1 (zh) 2021-12-07 2022-12-07 B7h6抗体及其应用

Country Status (12)

Country Link
US (1) US20240190968A1 (zh)
EP (1) EP4378956A1 (zh)
JP (1) JP2024529526A (zh)
KR (1) KR20240032996A (zh)
CN (1) CN114395045B (zh)
AU (1) AU2022404479A1 (zh)
CA (1) CA3227094A1 (zh)
IL (1) IL310514A (zh)
MX (1) MX2024003129A (zh)
TW (2) TW202426507A (zh)
WO (1) WO2023104062A1 (zh)
ZA (1) ZA202400968B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046407A2 (en) * 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
WO2013169691A1 (en) * 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
CN109310764A (zh) * 2016-04-15 2019-02-05 达特茅斯大学理事会 高亲和力b7-h6抗体和抗体片段
US20210107983A1 (en) * 2019-10-02 2021-04-15 Boehringer Ingelheim International Gmbh Multi-specific binding proteins for cancer treatment
CN114395045A (zh) * 2021-12-07 2022-04-26 合肥天港免疫药物有限公司 B7h6抗体及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2510011B2 (en) * 2009-12-09 2021-03-31 Institut National de la Santé et de la Recherche Médicale Monoclonal antibodies that bind b7h6 and uses thereof
CA2848333A1 (en) * 2011-09-13 2013-03-21 Deutsches Krebsforschungszentrum B7-h6 therapeutically active monoclonal antibody against b7-h6 polypeptide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046407A2 (en) * 2007-10-04 2009-04-09 Zymogenetics, Inc. B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
WO2013169691A1 (en) * 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
CN109310764A (zh) * 2016-04-15 2019-02-05 达特茅斯大学理事会 高亲和力b7-h6抗体和抗体片段
US20210107983A1 (en) * 2019-10-02 2021-04-15 Boehringer Ingelheim International Gmbh Multi-specific binding proteins for cancer treatment
CN114395045A (zh) * 2021-12-07 2022-04-26 合肥天港免疫药物有限公司 B7h6抗体及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHOTHIALESK, J.MOL.BIOL., vol. 196, 1987, pages 901 - 917
COLOMA, J.J. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 152 - 156
LARRICK, J.W ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 121 - 128

Also Published As

Publication number Publication date
TW202334228A (zh) 2023-09-01
KR20240032996A (ko) 2024-03-12
US20240190968A1 (en) 2024-06-13
CN114395045B (zh) 2023-06-09
JP2024529526A (ja) 2024-08-06
AU2022404479A1 (en) 2024-02-08
CA3227094A1 (en) 2023-06-15
ZA202400968B (en) 2024-03-27
IL310514A (en) 2024-03-01
CN114395045A (zh) 2022-04-26
EP4378956A1 (en) 2024-06-05
MX2024003129A (es) 2024-04-10
TW202426507A (zh) 2024-07-01
TWI848461B (zh) 2024-07-11

Similar Documents

Publication Publication Date Title
CN109384846B (zh) 能够结合tigit的抗体或其抗原结合片段及用途
US7696325B2 (en) Polypeptide inducing apoptosis
EP1262548B1 (en) Polypeptide inducing apoptosis
CN103554259A (zh) 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
US20240190968A1 (en) B7h6 antibody and use thereof
EP4223778A1 (en) Anti-claudin18.2 and cd3 bispecific antibody and use thereof
CN114369161B (zh) Mica抗体及其应用
WO2024125180A1 (zh) 抗cd155的抗体及其应用
WO2024140742A1 (zh) 抗cd94的抗体及其应用
JP2023505123A (ja) 医薬組成物、その製造方法及び用途
CN115960234B (zh) 抗cd16a的抗体及其应用
CN116063526A (zh) 抗pdl1的抗体及其用途
CN116143923A (zh) 高亲和力tigit抗体及其应用
JP2024519078A (ja) 抗ｃｅａ抗体及びその使用方法
CN114685657B (zh) 一种功能增强型抗体阻断剂的开发及其应用
KR20230169936A (ko) Garp 단백질 항체 및 이의 적용
CN114395043B (zh) Ncr3lg1抗体及其应用
CN114369162B (zh) 抗体及其应用
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
CN116813771A (zh) Cd112抗体及用途
KR20240135670A (ko) 항원 결합 단백질 및 이의 용도
CN116854819A (zh) 抗cd25抗体及其应用
CN118027208A (zh) 双特异性抗体及其应用
CN117924488A (zh) 阻断性cd40抗体及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22903484

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2022404479

Country of ref document: AU

Ref document number: 3227094

Country of ref document: CA

Ref document number: AU2022404479

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 310514

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2024102201

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2024506277

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20247004588

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020247004588

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2022404479

Country of ref document: AU

Date of ref document: 20221207

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022903484

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11202400581R

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2022903484

Country of ref document: EP

Effective date: 20240227

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024003846

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 112024003846

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240227